JPH051000B2 - - Google Patents
Info
- Publication number
- JPH051000B2 JPH051000B2 JP58501735A JP50173583A JPH051000B2 JP H051000 B2 JPH051000 B2 JP H051000B2 JP 58501735 A JP58501735 A JP 58501735A JP 50173583 A JP50173583 A JP 50173583A JP H051000 B2 JPH051000 B2 JP H051000B2
- Authority
- JP
- Japan
- Prior art keywords
- dtk
- serum
- activity
- present
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000694 effects Effects 0.000 abstract description 40
- 239000000758 substrate Substances 0.000 abstract description 30
- 238000000034 method Methods 0.000 abstract description 28
- 108010044467 Isoenzymes Proteins 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 21
- 229910019142 PO4 Inorganic materials 0.000 abstract description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 19
- 239000010452 phosphate Substances 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 10
- 230000009385 viral infection Effects 0.000 abstract description 9
- 239000007853 buffer solution Substances 0.000 abstract description 8
- 238000005259 measurement Methods 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 6
- 210000001124 body fluid Anatomy 0.000 abstract description 6
- 239000010839 body fluid Substances 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract description 3
- 229910052736 halogen Inorganic materials 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 99
- 108020004440 Thymidine kinase Proteins 0.000 description 99
- 210000002966 serum Anatomy 0.000 description 62
- 238000003556 assay Methods 0.000 description 37
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 10
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000007306 turnover Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'âdeoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 2
- 206010035724 Pneumonia mycoplasmal Diseases 0.000 description 2
- 206010037151 Psittacosis Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003622 anti-hsv Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 201000000901 ornithosis Diseases 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 102000048120 Galactokinases Human genes 0.000 description 1
- 108700023157 Galactokinases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- VSAISIQCTGDGPU-UHFFFAOYSA-N tetraphosphorus hexaoxide Chemical compound O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
Description
è«æ±ã®ç¯å²
ïŒ ããâåã¯åç©ã®äœæ¶²åã¯çŽ°èã®è©Šæã®dTk
ã¢ã€ãœã¶ã€ã ã¬ãã«ã枬å®ããæ¹æ³ã§ãã€ãŠãç
é žäŸäžäœããã³ç·©è¡ç³»ã®ååšã«ãããŠäžèšè©Šæã
äžèšã¢ã€ãœã¶ã€ã ã®ããã®åºè³ªãšåå¿ããã段é
ãšãçæããçé žåç©ã®éã枬å®ãã段éãšãã
æããäžèšã®éã¯äžèšã¢ã€ãœã¶ã€ã ã¬ãã«ã«æ¯äŸ
ãã ïœ PHç¯å²ïŒãïŒã§ã250mM以äžã®æ¿åºŠã§ååš
ããç·©è¡ç³»ãšã ïœ ãã®äžéšãæŸå°æ§æšèåããã²ã³ããã€2â²â
ããªãã·âïŒâãããŠãªãžã³ããæããããã
ïŒÃ10-9ãïŒÃ10-6ïŒã®ç¯å²ã®æ¿åºŠã§ååšãã
åºè³ªãšã ïœ 20mMãè¶ ããªãæ¿åºŠã§ååšããçé žäŸäžäœ
ãšãçµã¿åãããŠçšããããšãç¹åŸŽãšãããã
ãããã¯åç©ã®äœæ¶²ãŸãã¯çŽ°èã®è©Šæã®dTkã¢
ã€ãœã¶ã€ã ã®ã¬ãã«ã枬å®ããæ¹æ³ã ïŒ äžèšPHãçŽ6.5ãïŒãäžèšåºè³ªæ¿åºŠã10-8ã
ïŒÃ10-7ïŒãäžèšçé žäŸäžäœæ¿åºŠãçŽ0.5ã5mM
ã§ããè«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ äžèšç·©è¡ç©è³ªãæ¬è³ªçã«ããªã¹âãã¬ãšãŒã
ãå«ãŸãªãè«æ±ã®ç¯å²ç¬¬ïŒåã¯ç¬¬ïŒé èšèŒã®æ¹
æ³ã ïŒ äžèšçé žäŸäžäœãATPãšCTPãšããæã矀
ããéžã°ããè«æ±ã®ç¯å²ç¬¬ïŒïŒïŒåã¯ïŒé èšèŒã®
æ¹æ³ã ïŒ å©çšå¯èœãªæŸå°æ§æšèååºè³ªããåºè³ªç²æã
ãããçšååéå°ã®dTkã¢ã€ãœã¶ã€ã ããæã察
ç §ãçšããããšã«ãã€ãŠæž¬å®ãã段éããæãã
äžèšå¯Ÿç §ã¯äžèšçé žåç©ã®æŸå°èœæž¬å®åã«ãäžèš
è©Šæãšåæ§ã«åŠçãããè«æ±ã®ç¯å²ç¬¬ïŒïŒïŒïŒïŒ
åã¯ïŒé èšèŒã®æ¹æ³ã æçŽ°æž æ¬çºæã¯ããåã¯åç©ã®äœæ¶²äžåã¯çŽ°èè©Šæäž
ã®ã¢ã€ãœã¶ã€ã dTkïŒããªãã·ãããžã³ãããŒãŒïŒ
ã¬ãã«ã®æž¬å®æ³ã«é¢ãããã®ã§ãããæ¬çºæã¯æŽ
ã«ãçãè «çããã³æãçš®ã®ãŠã€ãŒã«ã¹æ§ææç
ã®ãããªãATPïŒã¢ããã·ã³äžçé žå¡©ïŒåªä»dTk
掻æ§ã«ããæ¯é ãããç æ°ã䞊ã³ã«HSVïŒåçŽç±
ç¹ãŠã€ãŒã«ã¹ïŒåããã³åããã³VZVïŒæ°Ž
çã»åž¯ç¶ç±ç¹ãŠã€ãŒã«ã¹ïŒææçã®ãããªCTP
ïŒã·ããžã³äžçé žå¡©ïŒåªä»dTk掻æ§ã«ãã€ãŠç¹åŸŽ
ã¥ããããç æ°ã®èšºæããã³äºåŸå€å®ã®ããã«äž
èšæ¹æ³ãå©çšããããšã«é¢ãããã®ã§ãããæ¬çº
æã¯åãdTkã¢ã€ãœã¶ã€ã ã®å決å®ã®ããã«äžèš
æ¹æ³ãå©çšããããšã«ãé¢ããã çºæã®èæ¯ çæ žçŽ°èã¯ãé µçŽ ããªãã·ãããžã³ãããŒãŒ
ïŒdTkïŒã®ãããã§ãããžãžã¬ãŒãåæã«ããã
äžéçæç©ã§ã¯ãªãããªãã·ãããžã³ïŒdTïŒã
å©çšããããšãã§ããããã®ãããdTkã¯dTã
DNAã代è¬ã«å°å ¥ãããµã«ãŽãšãŒãžé µçŽ ãšèã
ããããåºä¹³åç©çŽ°èã®äž»ãªdTkåã¯ã现èåè£
æã«ãããããã ãã§ãããããdTkã¯ã¹ãã€ãŽ
ãšã³ãžã€ãŒé µçŽ ãšç§°åŒãããã ãã现èäžã«ã¯ïŒçš®é¡ã®çŽ°èã¢ã€ãœã¶ã€ã ãã
ããšå ±åãããŠãããdTkâãšåŒã°ãã现è質
ãŸã«dTkã¯ãåè£çŽ°èïŒGIæãæïŒã®äžã«é©
éãããããïŒBelloïŒExptl.Cell.Res.89ïŒ263ïŒ
1974ïŒLittlefieldïŒBiochem.Biophys.
Acta.115ïŒ398ïŒ1966ïŒãéæ¢çŽ°èã«ã¯ã»ãšãã©
ååšããªããããã§ã¯ãã®é µçŽ ã¯ãæè²ïŒã¯ãã¢
ãœãŒã ïŒ17ã«ã¬ã©ã¯ããããŒãŒåº§ã®è¿ãã«ã³ãŒã
ãããã第äºã®çŽ°èã¢ã€ãœã¶ã€ã ã¯ãdTkâãš
åŒã°ããããã³ã³ããªã¢âã¢ã€ãœã¶ã€ã ã§ããã
ã³ã³ããªã¢åºè³ªäžã«ååšããããã®dTkã®æŽ»æ§ã¯
çš®ã ã®çŽ°èäžæ¯èŒçäžå®ã§ãããïŒAdelsteinãã
Devolop.Biol.26ïŒ537ïŒ1971ïŒãdTkâã¯æè²
äœ16ã«ãã€ãŠã³ãŒããããã掻æ§ã®å°ãããdTk
âãšåŒã°ãã第äžã®dTkã¯ãé£ç¶ç¶ä»£æ§çŽ°èç³»
HeLaããã³kBã«èŠåºãããããšãå ±åãããã®
ã¿ã§ãããããã³ã³ããªã¢èã®å åŽã«éãååšã
ããšèšãããŠããïŒKitã«ããèå¯ãPharmacol.
Ther.4ïŒ501ïŒ1979ïŒã ãã®ïŒçš®é¡ã®çŽ°èdTkã¯ãçååŠçæ§è³ªããã
ããç°ããdTkâãšdTkâã¯ãéåžžã«äŒŒãŠã
ãããäœçœ®ã®ä»ã«ãçé»ç¹é»æ°æ³³åã«ãã€ãŠïŒç°
ãªãçé»ç¹pIããã€ããïŒãåé»æ°æ³³å移å床ã«
ãã€ãŠåºå¥ããããdTkâããã³dTkâãšã¯
éã€ãŠãdTkâã¯ã·ããžã³âäžçé žå¡©ïŒCTPïŒ
ãçé žäŸäžäœãšããŠåã容ããdTTPïŒããªãã·
ãããžã³äžçé žå¡©ïŒâãã€ãŒãããã¯é»å®³ã«å¯Ÿã
ãŠä»ã®äºè ã»ã©ææã§ãªããdTkâã¯åãããª
ãã·ã·ããžã³ïŒdCïŒãçé žåããdCTPã«ãã€ãŠ
é»å®³ãããïŒKitã«ããèå¯ãPharmacol.
Ther.4ïŒ501ã1979ïŒã ãŠã€ãŒã«ã¹ã«é¢ããŠèšãã°ããŠã€ãŒã«ã¹ã²ãã
ã«ãã€ãŠèŠå®ãããç¹ç°çãªã¢ã€ãœã¶ã€ã ããã
ã«ãã¹çŸ€ããã³ããã¯ã¹çŸ€ã®ãŠã€ãŒã«ã¹ã«ããæ
æåŸã«ã现èäžã«èŠåºããããé µçŽ çã«ã¯ããã
ãŠã€ãŒã«ã¹ã«ç¹ç°çãªããã€ãã®çš®é¡ã®dTkã¯ã
ã¯ã¯ã·ãã¢dTkãé€ãã°dTkâã«äŒŒãŠããïŒã¯
ã¯ã·ãã¢dTkã¯CTPãçé žäŸäžäœãšããŠå©çšã
ãããšãã§ãããããªãã·ã·ããžã³ãçé žåãã
ããšãã§ããªãããã®dTkã¯ãé»æ°æ³³åã«ãã€ãŠ
容æã«ãã现èdTkãšåºå¥ãããïŒKitãã
Progr.Med.Virol.21ïŒ13ïŒKarger Basel 1975ïŒã
HSV dTksãVZV dTkããåºãçé žäŸäžäœã¹
ãã¯ãã©ã ãæããçš®ã ã®ããªããžã³ããã³ããª
ããžã³åæäœãåºè³ªãšããŠåã容ããïŒCheng
ããBiochem.Biophys.ActaïŒ452ïŒ370ïŒ1976ã
ããã³J.Virol.31ïŒ172ïŒ1979ïŒãdTkã¢ã€ãœã¶ã€
ã ãä»åšããdTã®dTmpïŒããªãã·ãããžã³âç
é žïŒãžã®å€æããdTåæäœã§ãã2â²âããªãã·
âïŒâãšãŒããŠãªãžã³ïŒIUdRïŒã«ãã€ãŠç«¶åç
ãããã¯ãåããããšã¯ä»¥åããç¥ãããŠããã
ãŠã€ãŒã«ã¹dTksè©Šéšã«ãããŠé«ãæ床ãåŸãã
ãã«ãæŸå°æ§æšèåIUdRãçŽæ¥ãåºè³ªãšããŠçš
ãåŸãããšãæã ã¯ç€ºããïŒGronowitz ïŒ
KallanderïŒInfec.Immun.29ïŒ425ïŒ1980ïŒã åè¿°ã®ããã«ã现èäžã«dTkâãåºçŸããã®
ã¯çŽ°èå¢æ®ã®æã§ãããååãã现èã«ã¯å€ãã
å°ããååšããªãïŒMunchâPeterson ïŒ
TyrstedïŒBiochim.Biophys.478ïŒ364ïŒ1977ïŒã
移æ€å¯èœã®ããŠã¹è «çã«ãããdTk掻æ§ã®ç 究ã«
ããã°ãå¢æ®é床ã«å¿ããŠdTk掻æ§ãé«ããªãã
ãšãæããã«ãããïŒBresnicket al.Cancer
Res.29ïŒ1969ãããã³Cancer Res.31ïŒ743ïŒ
1971ïŒãæè¿ã®å ±åã«ãããšãæªæ§éããžãã³æ§
ãªã³ãè «ããã³ãªã³ãæ§çœè¡ç ã«çœ¹ã€ãŠããè¥å¹²
ã®æ£è ã®æ¹æ¶è¡æ¶²ãªã³ãçã«ãdTkâãå¢å ã
ãŠããïŒEllims et alïŒCancer Res.41ïŒ691ãã
ã³Brit.J.HaemtolïŒãé«æ¿åºŠã®3HâdTïŒïŒÃ10-6
ïŒïŒãçšããåŸæ¥ã®dTkè©Šéšæ³ã«ãããšãdTk掻
æ§ã¯ãç æ°ã®é²ãã å°æ°ã®æ£è ã«èŠåºãããã«é
ããªãã€ãããã®ä»ã«ã¯ãdTkâãšdTkâã®
éå¥åæãè¡ã€ãå Žåã«éããdTk掻æ§ãäºåŸã
ãŒã«ãŒïŒæ瀺ç©ïŒãšããŠæž¬å®ããããšãã§ããã ãã®ããã«ãåŸæ¥ã¯ãATPãçé žäŸäžäœãšã
ãŠçšããã3Hâåã¯14CâæšèdTã®dTmpãžã®å€
æã远跡ããããšã«ãããdTk掻æ§ã枬å®ããŠã
ããæè¿ãæã ã¯ããŠã€ãŒã«ã¹dTkã¢ã€ãœã¶ã€ã
ã®ããã®é²æ©ããdTkã¢ãã»ã€ïŒæ€å®ïŒã·ã¹ãã
ãèæ¡ãããããã§ã¯ãåºè³ªãšããŠ125IâãšãŒã
ããªãã·ãŠãªãžã³ïŒIUdRïŒãçšããããããã®
æ¹æ³ã§ã¯ãæ床ãé«ãŸããã25HSVâææ现è
ã®ãããªå°ãã现èããdTkãæ€åºããããšãã§
ããããã«ãªã€ãããããšæ¯èŒããŠã3HâdTã
éåžž10-5ïŒæ¿åºŠã§çšããåŸæ¥ã®ã¢ãã»ã€ã§ã¯ãå°
ããšã450åå€ãã®é µçŽ ãå¿ èŠãšãããããããã
ãŠã€ãŒã«ã¹dTksã®ç 究ã«æçšã§ãããšã¯ããã
ãã®é²æ©ããã¢ãã»ã€ã·ã¹ãã ãããã®é µçŽ ãäž
å®å®ãªããããã€ãŠãé·æã«äºã现èdTkâã¢
ãã»ã€ã«ã¯äžé©åœã§ãã€ãããã®æ¹æ³ã§ã¯è¡æž äž
ã®åŸ®éã®dTkã®ååšãæ€åºããããšãã§ããªããš
ããããšãããŠã€ãŒã«ã¹dTké»æ¢æäœïŒdTkâ
abïŒã®åºçŸã«é¢ããè«žç 究ãã容æã«å°ãåºã
ãããããã®ç 究ã§ã¯ã275以äžã®ããè¡æž ã«ã€
ããŠdTkâabã¢ãã»ã€ãè¡ãããããè¡æž dTk
掻æ§ã®é»æ¢ã¯ïŒäŸã«èŠåºãããã ãã§ãã€ã
ïŒGronowitz ïŒ KašllanderïŒInfec.
Immun.29ïŒ425ïŒ1980ïŒGronowitz ïŒ
KašllanderïŒJ.Med.Virol.8ïŒ177ïŒ1981ïŒ
Kašllander et al.Infec.Immun.36ïŒ30ïŒ1982ïŒã çºæã®æŠèŠ æ¬çºæã®ç®çã¯ãçš®ã ã®ç®çã«ãããæªæ§è «ç
ã®ç£èŠãå«ããæãçš®ã®ãŠã€ãŒã«ã¹æ§ææçãã
ã³æªæ§è «çã®èšºæã®ããã®æ段ãæäŸããããšã«
ããã æ¬çºæã®ä»ã®ç®çã¯ãããããã³åç©ã®äœæ¶²ã
ãã³çŽ°èè©ŠæâäŸãã°è¡æž ãç±ç¹åæ³æ¶²ãé«æ¶²ã
å°æ°Žç±æ¶²ããã³ãã®çš®ã®èšåºæšæ¬âäžã«ãã埮é
ã®dTkãæ€åºã§ããé«æ床ã®ã¢ãã»ã€ã·ã¹ãã
ã§ãããã现èdTkâã®å¯äžãæå°ã«ãªããã
ã«èæ¡ãããã¢ãã»ã€ã·ã¹ãã ãæäŸããããšã«
ããã æ¬çºæã®ããã«ä»ã®ç®çã¯ãè «ççŸæ£ã®çºèŠã
ãã³äºåŸã®ããã«äœ¿çšããç æ°ã®å€åãç£èŠãã
åçºãçºèŠããããã®dTkâã¢ãã»ã€æ³ãæäŸ
ããããšã«ããã æ¬çºæã®ããã«ä»ã®ç®çã¯ãç麊现èåèºçãš
é¢é£ãã転移ã調ã¹ãå Žåã«ãäžèšã¢ãã»ã€æ³ã
å©çšããããšã«ããã æ¬çºæã®å¥ã®ç®çã¯ãè³âèé«ç³»ã«è»¢ç§»ããã
å Žåãé«æ¶²äžã®dTkã®æž¬å®ã«ãã€ãŠãçœè¡ç ã調
ã¹ãããã«äžèšã¢ãã»ã€æ³ãå©çšããããšã«ã
ãã æ¬çºæã®ããã«å¥ã®ç®çã¯ããŠã€ãŒã«ã¹æ§çŸæ£
ãšé¢é£ããæãçš®ã®ææçã®ããã®ã矀ç¹ç°çã
ãŒã«ãŒãšããŠã®äžèšã¢ãã»ã€æ³ã®å©çšã«ããã æ¬çºæã®ããã«ä»ã®ç®çã¯ãè¡æž åã¯å°æ°Žç±æ¶²
çã«ååšããããã«ãã¹ãŠã€ãŒã«ã¹ã«ç¹ç°çãª
dTksãç¹ç°çã«æ€åºããããã«äžèšã¢ãã»ã€æ³
ã®å€æ³ãå©çšããããšã«ããã æ¬çºæã®äžèšããã³ãã®ä»ã®ç®çã¯ãæ¬çºæã«
ããã¢ãã»ã€æ³ããã³ãã®é©çšã«é¢ããäžèšã®èš
è¿°ã«ããã詳现ã«èª¬æãããã æ¬çºæã¯ããã®ããã«ãè¡æž çã«ååšããdTk
ã¬ãã«ãç¹ã«dTkâã¬ãã«æž¬å®ã®ããã®é²æ©ã
ãã¢ãã»ã€æ³ãæäŸããããã®ã¢ãã»ã€ã·ã¹ãã
ã¯ãåŸæ¥æè¡ã®ã·ã¹ãã ããããªãæ床ãé«ãã
ãããŠæ床ãéåžžã«é«ãããã«ãéåžžã«ç°¡åã«å®
æœã§ãããã®ã¢ãã»ã€ã·ã¹ãã ããç çdTkã¬ã
ã«ã®ã¿ããªããå¥åžžè ã®æ£åžžã¬ãã«ã§ãã枬å®ã
ãã®ã«çšããããšãã§ããããšãå€æããïŒç¬¬ïŒ
å³ãšç¬¬ïŒå³ãæ¯èŒåç §ïŒããã®ã¢ãã»ã€ã·ã¹ãã
ã¯ãéåžžã«å®éçã§ãïŒæé以äžãçŽç·æ§ã¿ãŒã³
ãªãŒããŒãäžããŠãåçŸæ§ã®ããdTkâ枬å®å€
ã瀺ãããšãããã€ãã ãã§ãªãããŠã€ãŒã«ã¹
dTksã«é¢ããåŸæ¥æè¡ã®ã·ã¹ãã ããïŒãïŒå
é«ãã¿ãŒã³ãªãŒããŒãäžããããšãããã€ããåŸ
æ¥ã®ã¢ãã»ã€ã·ã¹ãã ãšæ¯èŒããŠéèŠãªããäžã€
ã®å©ç¹ã¯ãdTkâã®ã¿ãŒã³ãªãŒããŒãæ¯èŒçå°
ããããšã§ãããæªç²Ÿè£œè©Šæäžã§dTkâåã¯ãŠ
ã€ãŒã«ã¹dTkã枬å®ããå Žåããã®ã¢ã€ãœã¶ã€ã
ã¯æ¥µããããå¯äžããã®ã¿ã§ããã çé žäŸäžäœãšããŠATPã®ä»£ãã«CTPãçšãã
ãã®ã¢ãã»ã€ã·ã¹ãã ã®å€æ³ã¯ãåæãã¹ãè©Šæ
ããæãã«ãã¹ãŠã€ãŒã«ã¹dTké»æ¢è¡æž ãšå ±ã«ã«
ãããããã€ã³ããŠããŒããããšãã«ããã«ãã¹
ãŠã€ãŒã«ã¹èªå°dTkãç¹ç°çã«æ€åºããã®ã«æçš
ã§ããããšãããã€ãã æ¬æäžã«èšèŒããã奜éœåã®ãŸãæåŸ ä»¥äžã®æ
è¡çå¹æã¯ãæ¬çºæã«ããã°ãäœæ¿åºŠããã³äœã€
ãªã³åŒ·åºŠã®ç·©è¡ç³»ãç¹ç°ççš®é¡ã®æŸå°æ§æšèååº
質ïŒãã®æ¿åºŠã¯äœãïŒããã³äœæ¿åºŠã®çé žäŸäžäœ
ãšãçµåãããŠçšããããšã«ããåŸãããã åºãèŠå°ããã¿ãŠãæ¬çºæã¯ãããåã¯åç©ã®
äœæ¶²åã¯çŽ°èè©Šæäžã®dTkã¢ã€ãœã¶ã€ã ã¬ãã«ã
枬å®ããæ¹æ³ã§ãã€ãŠãäžèšè©Šæãçé žäŸäžäœã
ãã³ç·©è¡ç³»ã®ååšäžã§äžèšã¢ã€ãœã¶ã€ã ã®ããã®
åºè³ªãšåå¿ãããçæããçé žåç©ã®éã枬å®
ãããã®éã¯äžèšã¢ã€ãœã¶ã€ã ã¬ãã«ãšæ¯äŸãã
ãšããæ¹æ³ã«é¢ãããã®ã§ãããæ¬çºæã«ããäž
èšæ¹æ³ã¯ã ïœ PHç¯å²ïŒãïŒãæ¿åºŠ250mM以äžã®ç·©è¡ç³»ãšã ïœ äžéšã¯æŸå°æ§æšèåâïŒâããã²ã³ãæãã
2â²âããªãã·âïŒâãããŠãªãžã³ããæããã
ã®æ¿åºŠãïŒÃ10-9ãïŒÃ10-6ïŒã§ããåºè³ªãšã ïœ 20mM以äžã®æ¿åºŠã§ååšããçé žäŸäžäœãšã
çµã¿åãããŠçšãããšããç¹åŸŽãæããã åºè³ªãšããŠ125IâIUdRãçšãã以åã«å ±åã
ããã¢ãã»ã€ã·ã¹ãã ãšéã€ãŠãæ¬çºæã«ããã¢
ãã»ã€ã·ã¹ãã ã§ã¯çŽ°èdTkâã®ããã®åºè³ªã
ïŒæé以äžãçŽç·æ§ã¿ãŒã³ãªãŒããŒãäžãã第ïŒ
å³ã«èŠãããããã«æ€åºæ床ãåçã«å¢å ããã
ãã®å³ã¯æ¬çºæã«ããã¢ãã»ã€ç³»ïŒâââââ
âïŒãšäžèšå è¡æè¡ã®ã¢ãã»ã€ç³»ïŒââ³ââ³ââ³
âïŒãšã®æ¯èŒã§ããïŒGronowitz ïŒ
KallanderïŒInfec.Immun.29ïŒ425ïŒ1980ïŒãïŒ
çœè¡ç æ£è ã«ç±æ¥ããããdTkâãå«ãïŒè¡
æž ãïŒçŽ°èå¹é€èµ·æºã®HSVå2dTkãå©çšå¯èœ
ã®ç·125IâIUdRã¯550Ã103cpmã§ãã€ãã
ã¢ã€ãœã¶ã€ã ã¬ãã«ã枬å®ããæ¹æ³ã§ãã€ãŠãç
é žäŸäžäœããã³ç·©è¡ç³»ã®ååšã«ãããŠäžèšè©Šæã
äžèšã¢ã€ãœã¶ã€ã ã®ããã®åºè³ªãšåå¿ããã段é
ãšãçæããçé žåç©ã®éã枬å®ãã段éãšãã
æããäžèšã®éã¯äžèšã¢ã€ãœã¶ã€ã ã¬ãã«ã«æ¯äŸ
ãã ïœ PHç¯å²ïŒãïŒã§ã250mM以äžã®æ¿åºŠã§ååš
ããç·©è¡ç³»ãšã ïœ ãã®äžéšãæŸå°æ§æšèåããã²ã³ããã€2â²â
ããªãã·âïŒâãããŠãªãžã³ããæããããã
ïŒÃ10-9ãïŒÃ10-6ïŒã®ç¯å²ã®æ¿åºŠã§ååšãã
åºè³ªãšã ïœ 20mMãè¶ ããªãæ¿åºŠã§ååšããçé žäŸäžäœ
ãšãçµã¿åãããŠçšããããšãç¹åŸŽãšãããã
ãããã¯åç©ã®äœæ¶²ãŸãã¯çŽ°èã®è©Šæã®dTkã¢
ã€ãœã¶ã€ã ã®ã¬ãã«ã枬å®ããæ¹æ³ã ïŒ äžèšPHãçŽ6.5ãïŒãäžèšåºè³ªæ¿åºŠã10-8ã
ïŒÃ10-7ïŒãäžèšçé žäŸäžäœæ¿åºŠãçŽ0.5ã5mM
ã§ããè«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ äžèšç·©è¡ç©è³ªãæ¬è³ªçã«ããªã¹âãã¬ãšãŒã
ãå«ãŸãªãè«æ±ã®ç¯å²ç¬¬ïŒåã¯ç¬¬ïŒé èšèŒã®æ¹
æ³ã ïŒ äžèšçé žäŸäžäœãATPãšCTPãšããæã矀
ããéžã°ããè«æ±ã®ç¯å²ç¬¬ïŒïŒïŒåã¯ïŒé èšèŒã®
æ¹æ³ã ïŒ å©çšå¯èœãªæŸå°æ§æšèååºè³ªããåºè³ªç²æã
ãããçšååéå°ã®dTkã¢ã€ãœã¶ã€ã ããæã察
ç §ãçšããããšã«ãã€ãŠæž¬å®ãã段éããæãã
äžèšå¯Ÿç §ã¯äžèšçé žåç©ã®æŸå°èœæž¬å®åã«ãäžèš
è©Šæãšåæ§ã«åŠçãããè«æ±ã®ç¯å²ç¬¬ïŒïŒïŒïŒïŒ
åã¯ïŒé èšèŒã®æ¹æ³ã æçŽ°æž æ¬çºæã¯ããåã¯åç©ã®äœæ¶²äžåã¯çŽ°èè©Šæäž
ã®ã¢ã€ãœã¶ã€ã dTkïŒããªãã·ãããžã³ãããŒãŒïŒ
ã¬ãã«ã®æž¬å®æ³ã«é¢ãããã®ã§ãããæ¬çºæã¯æŽ
ã«ãçãè «çããã³æãçš®ã®ãŠã€ãŒã«ã¹æ§ææç
ã®ãããªãATPïŒã¢ããã·ã³äžçé žå¡©ïŒåªä»dTk
掻æ§ã«ããæ¯é ãããç æ°ã䞊ã³ã«HSVïŒåçŽç±
ç¹ãŠã€ãŒã«ã¹ïŒåããã³åããã³VZVïŒæ°Ž
çã»åž¯ç¶ç±ç¹ãŠã€ãŒã«ã¹ïŒææçã®ãããªCTP
ïŒã·ããžã³äžçé žå¡©ïŒåªä»dTk掻æ§ã«ãã€ãŠç¹åŸŽ
ã¥ããããç æ°ã®èšºæããã³äºåŸå€å®ã®ããã«äž
èšæ¹æ³ãå©çšããããšã«é¢ãããã®ã§ãããæ¬çº
æã¯åãdTkã¢ã€ãœã¶ã€ã ã®å決å®ã®ããã«äžèš
æ¹æ³ãå©çšããããšã«ãé¢ããã çºæã®èæ¯ çæ žçŽ°èã¯ãé µçŽ ããªãã·ãããžã³ãããŒãŒ
ïŒdTkïŒã®ãããã§ãããžãžã¬ãŒãåæã«ããã
äžéçæç©ã§ã¯ãªãããªãã·ãããžã³ïŒdTïŒã
å©çšããããšãã§ããããã®ãããdTkã¯dTã
DNAã代è¬ã«å°å ¥ãããµã«ãŽãšãŒãžé µçŽ ãšèã
ããããåºä¹³åç©çŽ°èã®äž»ãªdTkåã¯ã现èåè£
æã«ãããããã ãã§ãããããdTkã¯ã¹ãã€ãŽ
ãšã³ãžã€ãŒé µçŽ ãšç§°åŒãããã ãã现èäžã«ã¯ïŒçš®é¡ã®çŽ°èã¢ã€ãœã¶ã€ã ãã
ããšå ±åãããŠãããdTkâãšåŒã°ãã现è質
ãŸã«dTkã¯ãåè£çŽ°èïŒGIæãæïŒã®äžã«é©
éãããããïŒBelloïŒExptl.Cell.Res.89ïŒ263ïŒ
1974ïŒLittlefieldïŒBiochem.Biophys.
Acta.115ïŒ398ïŒ1966ïŒãéæ¢çŽ°èã«ã¯ã»ãšãã©
ååšããªããããã§ã¯ãã®é µçŽ ã¯ãæè²ïŒã¯ãã¢
ãœãŒã ïŒ17ã«ã¬ã©ã¯ããããŒãŒåº§ã®è¿ãã«ã³ãŒã
ãããã第äºã®çŽ°èã¢ã€ãœã¶ã€ã ã¯ãdTkâãš
åŒã°ããããã³ã³ããªã¢âã¢ã€ãœã¶ã€ã ã§ããã
ã³ã³ããªã¢åºè³ªäžã«ååšããããã®dTkã®æŽ»æ§ã¯
çš®ã ã®çŽ°èäžæ¯èŒçäžå®ã§ãããïŒAdelsteinãã
Devolop.Biol.26ïŒ537ïŒ1971ïŒãdTkâã¯æè²
äœ16ã«ãã€ãŠã³ãŒããããã掻æ§ã®å°ãããdTk
âãšåŒã°ãã第äžã®dTkã¯ãé£ç¶ç¶ä»£æ§çŽ°èç³»
HeLaããã³kBã«èŠåºãããããšãå ±åãããã®
ã¿ã§ãããããã³ã³ããªã¢èã®å åŽã«éãååšã
ããšèšãããŠããïŒKitã«ããèå¯ãPharmacol.
Ther.4ïŒ501ïŒ1979ïŒã ãã®ïŒçš®é¡ã®çŽ°èdTkã¯ãçååŠçæ§è³ªããã
ããç°ããdTkâãšdTkâã¯ãéåžžã«äŒŒãŠã
ãããäœçœ®ã®ä»ã«ãçé»ç¹é»æ°æ³³åã«ãã€ãŠïŒç°
ãªãçé»ç¹pIããã€ããïŒãåé»æ°æ³³å移å床ã«
ãã€ãŠåºå¥ããããdTkâããã³dTkâãšã¯
éã€ãŠãdTkâã¯ã·ããžã³âäžçé žå¡©ïŒCTPïŒ
ãçé žäŸäžäœãšããŠåã容ããdTTPïŒããªãã·
ãããžã³äžçé žå¡©ïŒâãã€ãŒãããã¯é»å®³ã«å¯Ÿã
ãŠä»ã®äºè ã»ã©ææã§ãªããdTkâã¯åãããª
ãã·ã·ããžã³ïŒdCïŒãçé žåããdCTPã«ãã€ãŠ
é»å®³ãããïŒKitã«ããèå¯ãPharmacol.
Ther.4ïŒ501ã1979ïŒã ãŠã€ãŒã«ã¹ã«é¢ããŠèšãã°ããŠã€ãŒã«ã¹ã²ãã
ã«ãã€ãŠèŠå®ãããç¹ç°çãªã¢ã€ãœã¶ã€ã ããã
ã«ãã¹çŸ€ããã³ããã¯ã¹çŸ€ã®ãŠã€ãŒã«ã¹ã«ããæ
æåŸã«ã现èäžã«èŠåºããããé µçŽ çã«ã¯ããã
ãŠã€ãŒã«ã¹ã«ç¹ç°çãªããã€ãã®çš®é¡ã®dTkã¯ã
ã¯ã¯ã·ãã¢dTkãé€ãã°dTkâã«äŒŒãŠããïŒã¯
ã¯ã·ãã¢dTkã¯CTPãçé žäŸäžäœãšããŠå©çšã
ãããšãã§ãããããªãã·ã·ããžã³ãçé žåãã
ããšãã§ããªãããã®dTkã¯ãé»æ°æ³³åã«ãã€ãŠ
容æã«ãã现èdTkãšåºå¥ãããïŒKitãã
Progr.Med.Virol.21ïŒ13ïŒKarger Basel 1975ïŒã
HSV dTksãVZV dTkããåºãçé žäŸäžäœã¹
ãã¯ãã©ã ãæããçš®ã ã®ããªããžã³ããã³ããª
ããžã³åæäœãåºè³ªãšããŠåã容ããïŒCheng
ããBiochem.Biophys.ActaïŒ452ïŒ370ïŒ1976ã
ããã³J.Virol.31ïŒ172ïŒ1979ïŒãdTkã¢ã€ãœã¶ã€
ã ãä»åšããdTã®dTmpïŒããªãã·ãããžã³âç
é žïŒãžã®å€æããdTåæäœã§ãã2â²âããªãã·
âïŒâãšãŒããŠãªãžã³ïŒIUdRïŒã«ãã€ãŠç«¶åç
ãããã¯ãåããããšã¯ä»¥åããç¥ãããŠããã
ãŠã€ãŒã«ã¹dTksè©Šéšã«ãããŠé«ãæ床ãåŸãã
ãã«ãæŸå°æ§æšèåIUdRãçŽæ¥ãåºè³ªãšããŠçš
ãåŸãããšãæã ã¯ç€ºããïŒGronowitz ïŒ
KallanderïŒInfec.Immun.29ïŒ425ïŒ1980ïŒã åè¿°ã®ããã«ã现èäžã«dTkâãåºçŸããã®
ã¯çŽ°èå¢æ®ã®æã§ãããååãã现èã«ã¯å€ãã
å°ããååšããªãïŒMunchâPeterson ïŒ
TyrstedïŒBiochim.Biophys.478ïŒ364ïŒ1977ïŒã
移æ€å¯èœã®ããŠã¹è «çã«ãããdTk掻æ§ã®ç 究ã«
ããã°ãå¢æ®é床ã«å¿ããŠdTk掻æ§ãé«ããªãã
ãšãæããã«ãããïŒBresnicket al.Cancer
Res.29ïŒ1969ãããã³Cancer Res.31ïŒ743ïŒ
1971ïŒãæè¿ã®å ±åã«ãããšãæªæ§éããžãã³æ§
ãªã³ãè «ããã³ãªã³ãæ§çœè¡ç ã«çœ¹ã€ãŠããè¥å¹²
ã®æ£è ã®æ¹æ¶è¡æ¶²ãªã³ãçã«ãdTkâãå¢å ã
ãŠããïŒEllims et alïŒCancer Res.41ïŒ691ãã
ã³Brit.J.HaemtolïŒãé«æ¿åºŠã®3HâdTïŒïŒÃ10-6
ïŒïŒãçšããåŸæ¥ã®dTkè©Šéšæ³ã«ãããšãdTk掻
æ§ã¯ãç æ°ã®é²ãã å°æ°ã®æ£è ã«èŠåºãããã«é
ããªãã€ãããã®ä»ã«ã¯ãdTkâãšdTkâã®
éå¥åæãè¡ã€ãå Žåã«éããdTk掻æ§ãäºåŸã
ãŒã«ãŒïŒæ瀺ç©ïŒãšããŠæž¬å®ããããšãã§ããã ãã®ããã«ãåŸæ¥ã¯ãATPãçé žäŸäžäœãšã
ãŠçšããã3Hâåã¯14CâæšèdTã®dTmpãžã®å€
æã远跡ããããšã«ãããdTk掻æ§ã枬å®ããŠã
ããæè¿ãæã ã¯ããŠã€ãŒã«ã¹dTkã¢ã€ãœã¶ã€ã
ã®ããã®é²æ©ããdTkã¢ãã»ã€ïŒæ€å®ïŒã·ã¹ãã
ãèæ¡ãããããã§ã¯ãåºè³ªãšããŠ125IâãšãŒã
ããªãã·ãŠãªãžã³ïŒIUdRïŒãçšããããããã®
æ¹æ³ã§ã¯ãæ床ãé«ãŸããã25HSVâææ现è
ã®ãããªå°ãã现èããdTkãæ€åºããããšãã§
ããããã«ãªã€ãããããšæ¯èŒããŠã3HâdTã
éåžž10-5ïŒæ¿åºŠã§çšããåŸæ¥ã®ã¢ãã»ã€ã§ã¯ãå°
ããšã450åå€ãã®é µçŽ ãå¿ èŠãšãããããããã
ãŠã€ãŒã«ã¹dTksã®ç 究ã«æçšã§ãããšã¯ããã
ãã®é²æ©ããã¢ãã»ã€ã·ã¹ãã ãããã®é µçŽ ãäž
å®å®ãªããããã€ãŠãé·æã«äºã现èdTkâã¢
ãã»ã€ã«ã¯äžé©åœã§ãã€ãããã®æ¹æ³ã§ã¯è¡æž äž
ã®åŸ®éã®dTkã®ååšãæ€åºããããšãã§ããªããš
ããããšãããŠã€ãŒã«ã¹dTké»æ¢æäœïŒdTkâ
abïŒã®åºçŸã«é¢ããè«žç 究ãã容æã«å°ãåºã
ãããããã®ç 究ã§ã¯ã275以äžã®ããè¡æž ã«ã€
ããŠdTkâabã¢ãã»ã€ãè¡ãããããè¡æž dTk
掻æ§ã®é»æ¢ã¯ïŒäŸã«èŠåºãããã ãã§ãã€ã
ïŒGronowitz ïŒ KašllanderïŒInfec.
Immun.29ïŒ425ïŒ1980ïŒGronowitz ïŒ
KašllanderïŒJ.Med.Virol.8ïŒ177ïŒ1981ïŒ
Kašllander et al.Infec.Immun.36ïŒ30ïŒ1982ïŒã çºæã®æŠèŠ æ¬çºæã®ç®çã¯ãçš®ã ã®ç®çã«ãããæªæ§è «ç
ã®ç£èŠãå«ããæãçš®ã®ãŠã€ãŒã«ã¹æ§ææçãã
ã³æªæ§è «çã®èšºæã®ããã®æ段ãæäŸããããšã«
ããã æ¬çºæã®ä»ã®ç®çã¯ãããããã³åç©ã®äœæ¶²ã
ãã³çŽ°èè©ŠæâäŸãã°è¡æž ãç±ç¹åæ³æ¶²ãé«æ¶²ã
å°æ°Žç±æ¶²ããã³ãã®çš®ã®èšåºæšæ¬âäžã«ãã埮é
ã®dTkãæ€åºã§ããé«æ床ã®ã¢ãã»ã€ã·ã¹ãã
ã§ãããã现èdTkâã®å¯äžãæå°ã«ãªããã
ã«èæ¡ãããã¢ãã»ã€ã·ã¹ãã ãæäŸããããšã«
ããã æ¬çºæã®ããã«ä»ã®ç®çã¯ãè «ççŸæ£ã®çºèŠã
ãã³äºåŸã®ããã«äœ¿çšããç æ°ã®å€åãç£èŠãã
åçºãçºèŠããããã®dTkâã¢ãã»ã€æ³ãæäŸ
ããããšã«ããã æ¬çºæã®ããã«ä»ã®ç®çã¯ãç麊现èåèºçãš
é¢é£ãã転移ã調ã¹ãå Žåã«ãäžèšã¢ãã»ã€æ³ã
å©çšããããšã«ããã æ¬çºæã®å¥ã®ç®çã¯ãè³âèé«ç³»ã«è»¢ç§»ããã
å Žåãé«æ¶²äžã®dTkã®æž¬å®ã«ãã€ãŠãçœè¡ç ã調
ã¹ãããã«äžèšã¢ãã»ã€æ³ãå©çšããããšã«ã
ãã æ¬çºæã®ããã«å¥ã®ç®çã¯ããŠã€ãŒã«ã¹æ§çŸæ£
ãšé¢é£ããæãçš®ã®ææçã®ããã®ã矀ç¹ç°çã
ãŒã«ãŒãšããŠã®äžèšã¢ãã»ã€æ³ã®å©çšã«ããã æ¬çºæã®ããã«ä»ã®ç®çã¯ãè¡æž åã¯å°æ°Žç±æ¶²
çã«ååšããããã«ãã¹ãŠã€ãŒã«ã¹ã«ç¹ç°çãª
dTksãç¹ç°çã«æ€åºããããã«äžèšã¢ãã»ã€æ³
ã®å€æ³ãå©çšããããšã«ããã æ¬çºæã®äžèšããã³ãã®ä»ã®ç®çã¯ãæ¬çºæã«
ããã¢ãã»ã€æ³ããã³ãã®é©çšã«é¢ããäžèšã®èš
è¿°ã«ããã詳现ã«èª¬æãããã æ¬çºæã¯ããã®ããã«ãè¡æž çã«ååšããdTk
ã¬ãã«ãç¹ã«dTkâã¬ãã«æž¬å®ã®ããã®é²æ©ã
ãã¢ãã»ã€æ³ãæäŸããããã®ã¢ãã»ã€ã·ã¹ãã
ã¯ãåŸæ¥æè¡ã®ã·ã¹ãã ããããªãæ床ãé«ãã
ãããŠæ床ãéåžžã«é«ãããã«ãéåžžã«ç°¡åã«å®
æœã§ãããã®ã¢ãã»ã€ã·ã¹ãã ããç çdTkã¬ã
ã«ã®ã¿ããªããå¥åžžè ã®æ£åžžã¬ãã«ã§ãã枬å®ã
ãã®ã«çšããããšãã§ããããšãå€æããïŒç¬¬ïŒ
å³ãšç¬¬ïŒå³ãæ¯èŒåç §ïŒããã®ã¢ãã»ã€ã·ã¹ãã
ã¯ãéåžžã«å®éçã§ãïŒæé以äžãçŽç·æ§ã¿ãŒã³
ãªãŒããŒãäžããŠãåçŸæ§ã®ããdTkâ枬å®å€
ã瀺ãããšãããã€ãã ãã§ãªãããŠã€ãŒã«ã¹
dTksã«é¢ããåŸæ¥æè¡ã®ã·ã¹ãã ããïŒãïŒå
é«ãã¿ãŒã³ãªãŒããŒãäžããããšãããã€ããåŸ
æ¥ã®ã¢ãã»ã€ã·ã¹ãã ãšæ¯èŒããŠéèŠãªããäžã€
ã®å©ç¹ã¯ãdTkâã®ã¿ãŒã³ãªãŒããŒãæ¯èŒçå°
ããããšã§ãããæªç²Ÿè£œè©Šæäžã§dTkâåã¯ãŠ
ã€ãŒã«ã¹dTkã枬å®ããå Žåããã®ã¢ã€ãœã¶ã€ã
ã¯æ¥µããããå¯äžããã®ã¿ã§ããã çé žäŸäžäœãšããŠATPã®ä»£ãã«CTPãçšãã
ãã®ã¢ãã»ã€ã·ã¹ãã ã®å€æ³ã¯ãåæãã¹ãè©Šæ
ããæãã«ãã¹ãŠã€ãŒã«ã¹dTké»æ¢è¡æž ãšå ±ã«ã«
ãããããã€ã³ããŠããŒããããšãã«ããã«ãã¹
ãŠã€ãŒã«ã¹èªå°dTkãç¹ç°çã«æ€åºããã®ã«æçš
ã§ããããšãããã€ãã æ¬æäžã«èšèŒããã奜éœåã®ãŸãæåŸ ä»¥äžã®æ
è¡çå¹æã¯ãæ¬çºæã«ããã°ãäœæ¿åºŠããã³äœã€
ãªã³åŒ·åºŠã®ç·©è¡ç³»ãç¹ç°ççš®é¡ã®æŸå°æ§æšèååº
質ïŒãã®æ¿åºŠã¯äœãïŒããã³äœæ¿åºŠã®çé žäŸäžäœ
ãšãçµåãããŠçšããããšã«ããåŸãããã åºãèŠå°ããã¿ãŠãæ¬çºæã¯ãããåã¯åç©ã®
äœæ¶²åã¯çŽ°èè©Šæäžã®dTkã¢ã€ãœã¶ã€ã ã¬ãã«ã
枬å®ããæ¹æ³ã§ãã€ãŠãäžèšè©Šæãçé žäŸäžäœã
ãã³ç·©è¡ç³»ã®ååšäžã§äžèšã¢ã€ãœã¶ã€ã ã®ããã®
åºè³ªãšåå¿ãããçæããçé žåç©ã®éã枬å®
ãããã®éã¯äžèšã¢ã€ãœã¶ã€ã ã¬ãã«ãšæ¯äŸãã
ãšããæ¹æ³ã«é¢ãããã®ã§ãããæ¬çºæã«ããäž
èšæ¹æ³ã¯ã ïœ PHç¯å²ïŒãïŒãæ¿åºŠ250mM以äžã®ç·©è¡ç³»ãšã ïœ äžéšã¯æŸå°æ§æšèåâïŒâããã²ã³ãæãã
2â²âããªãã·âïŒâãããŠãªãžã³ããæããã
ã®æ¿åºŠãïŒÃ10-9ãïŒÃ10-6ïŒã§ããåºè³ªãšã ïœ 20mM以äžã®æ¿åºŠã§ååšããçé žäŸäžäœãšã
çµã¿åãããŠçšãããšããç¹åŸŽãæããã åºè³ªãšããŠ125IâIUdRãçšãã以åã«å ±åã
ããã¢ãã»ã€ã·ã¹ãã ãšéã€ãŠãæ¬çºæã«ããã¢
ãã»ã€ã·ã¹ãã ã§ã¯çŽ°èdTkâã®ããã®åºè³ªã
ïŒæé以äžãçŽç·æ§ã¿ãŒã³ãªãŒããŒãäžãã第ïŒ
å³ã«èŠãããããã«æ€åºæ床ãåçã«å¢å ããã
ãã®å³ã¯æ¬çºæã«ããã¢ãã»ã€ç³»ïŒâââââ
âïŒãšäžèšå è¡æè¡ã®ã¢ãã»ã€ç³»ïŒââ³ââ³ââ³
âïŒãšã®æ¯èŒã§ããïŒGronowitz ïŒ
KallanderïŒInfec.Immun.29ïŒ425ïŒ1980ïŒãïŒ
çœè¡ç æ£è ã«ç±æ¥ããããdTkâãå«ãïŒè¡
æž ãïŒçŽ°èå¹é€èµ·æºã®HSVå2dTkãå©çšå¯èœ
ã®ç·125IâIUdRã¯550Ã103cpmã§ãã€ãã
第ïŒïŒ¡ããã³ïŒ¢å³ã¯ãæéã«å¯ŸããŠããããã
ãé µçŽ æŽ»æ§ã瀺ããæãè¿ãå è¡æè¡ã«æ¯èŒã
ãŠãæ¬çºææ¹æ³ã®æ床ãåçã«é²æ©ããŠããããš
ã瀺ãã°ã©ãã§ããã 第ïŒïŒ¡ããã³ïŒ¢å³ã¯ãâèå±€ã¯ãããã°ã©ãã«
ãã€ãŠâæ¬çºæã«ãã奜ãŸããåºè³ª125IâIUdR
ã®æŸå°ååŠççŽåºŠã®è²¯èµäžã«ãããæžå°ã瀺ãã°
ã©ãã§ããã 第ïŒå³ã¯ãå éšåºè³ªã³ã³ãããŒã«ïŒå¯Ÿç §ïŒãçš
ããæé µçŽ æŽ»æ§ãåäœã§èšç®ããããšã説æãã
ã°ã©ãã§ããã 第ïŒå³ã¯ãdTk枬å®ã«ãããŠè¡æž äžã®é«æ¿åºŠã®
é»æ¢ç圱é¿ã瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ãç°ãªãèšåºæšæ¬ã«ããããŠã€ãŒã«ã¹
dTkã®å決å®ïŒã¿ã€ãã³ã°ïŒããã°ã©ãã«ãã€ãŠ
瀺ãã 第ïŒå³ã¯ãäŸè¡è ããã³åŠå©Šã«ãããdTk掻æ§
ã®æ£åžžååžã瀺ãå³ã§ããã 第ïŒå³ã¯ãäŒææ§åæ žçæ£è ã®è¡æž äžã§æ¬çºæ
ã«äŸã€ãŠæž¬å®ããdTk掻æ§ããç æ°çºçåŸã®çµé
æéãšé¢é£ã¥ããŠç€ºããå³ã§ããã 第ïŒå³ã¯ãçš®ã ã®ãŠã€ãŒã«ã¹æ§ææçããã€ã³
ãã©ãºãèºçããã³ãªãŠã ç ã«ããã€ãæ£è ã®è¡
æž äžã«èŠåºãããdTk掻æ§ãæããã«ããå³ã§ã
ãã 第ïŒïœããã³ïŒïœå³ã¯ãæ¬çºæã«åŸã€ãŠæž¬å®ã
ãè¡æž dTk掻æ§ãšãNHLæ£è ã®ç æãšã®éã®çž
é¢é¢ä¿ã瀺ãå³ã§ããã 第ïŒïŒïœããã³ïŒïŒïœå³ã¯ãNHLæ£è ã®çå
ã®ç¢ºçãšãæ¬çºæã«åŸã€ãŠæž¬å®ããè¡æž dTkã¬ã
ã«ãšã®é¢ä¿ã瀺ãã 第ïŒïŒããã³ïŒïŒå³ã¯ãçš®ã ã®èšåºççµéã蟿
ã€ãNHLæ£è ã®è¡æž dTkã¬ãã«ã®çµéç 究ã説
æããå³ã§ããã 奜ãŸããæ æ§ã®èª¬æ æ¬çºæã®å¥œãŸããæ æ§ã«ãããŠã¯ãäžèšç·©è¡ç³»
ã¯çŽ150mM以äžãç¹ã«å¥œãŸããã¯çŽ100mMã®æ¿
床ã§ãããç·©è¡æ¶²ã®å¥œãŸããPHã¯6.5ãïŒã®ç¯å²
ã§ãç¹ã«çŽ7.4ã奜ãŸããããã¬ã€ã³é žå¡©ãå«æ
ããªãç·©è¡æ¶²ãåå¿æ§ã«å¯ãã¢ããåºåã¯ç¬¬äžã¢
ããåºãæ¬ ãç·©è¡æ¶²ãç¹ã«ããªã¹âãã¬ãšãŒãã
å®è³ªçã«å«æããªãç·©è¡æ¶²ã§æãè¯ãçµæãåŸã
ããHEPESç·©è¡æ¶²ãç¹ã«å¥œãŸããã åºè³ªã¯æŸå°æ§æšèåãããžã³åæäœãç¹ã«2â²â
ããªãã·âïŒâããã²ã³âãŠãªãžã³ã§ããã¹ã
ã§ããã®å Žåãã®æšèã¯åå¿æ§ããã²ã³åäœå çŽ
ã§ããããšã奜ãŸããã奜ãŸããåºè³ªã¯125Iâ
2â²âããªãã·âïŒâãšãŒããŠãªãžã³ã§ããã奜ãŸ
ããåºè³ªæ¿åºŠã¯ïŒÃ10-8ãïŒÃ10-7ã®ç¯å²å ãç¹
ã«çŽ10-7ïŒã§ããã dTkâ枬å®ã®ããã«å¥œãŸããçé žäŸäžäœã¯
ATPã§ããŠã€ãŒã«ã¹dTk枬å®ã®ããã«å¥œãŸãã
çé žäŸäžäœã¯CTPã§ãããçé žäŸäžäœã®å¥œãŸã
ãæ¿åºŠã¯çŽ10mM以äžãç¹ã«çŽ0.5ã5mMã§ã
ããæ¬æ¥ATPããã³CTPãšåæ§ã®ã¢ã€ãœã¶ã€ã
ç¹ç°æ§ããã€ããšãç¥ãããŠããçé žäŸäžäœãçš
ããŠãããã Mg2+ã¯çé žäŸäžäœãšå°ããšãçã¢ã«æ¿åºŠã§å
åšããã®ã奜ãŸããããžããªã¹ã¬ã€ããŒã«ã®ãã
ãªéå å€ãååšããã®ã奜ãŸããã çé žåçæç©ã¯æ¬æ¥ç¥ãããŠããæ¹æ³ã«ãã€ãŠ
枬å®ã§ããïŒäŸãã°GronowitzãšKallanderïŒ
Infec.Immun.29ïŒ425ïŒ1980åç §ïŒã äŸãã°è¡æž åã¯ç±ç¹åæ³ç©ã®ãããªèšåºæšæ¬ã«
ãããdTk掻æ§ãæ€åºããããã«æ¬çºæã«ããã¢
ãã»ã€ã·ã¹ãã ãé©çšããããšã¯ãæãçš®ã®ãŠã€
ãŒã«ã¹ææçããã³æªæ§è «çã®èšºæã®ããã®æ°ã
ãæ段ããããããåè¿°ããæ¹æ³ã«ããåäžã®
dTkã¢ãã»ã€ã§åŸãããç°åžžãªè¡æž dTkã¬ãã«
ïŒäŸãã°ãïŒ10åäœïŒã¯ãäºåŸèšºæçã«äœ¿çšããå Ž
åãããããããŒã«ãŒã«ãªãããšãå€æãããŸã
åæ§ã«é£ç¶dTkå€ãæªæ§çŸæ£ã®é²è¡åã¯éè¡ãç£
èŠããå Žåã®ããããããŒã«ãŒã«ãªãããšãå€æ
ãããæŽã«ããããã®æ£è ã§ã¯è¡æž dTkã¬ãã«ã
åçºã®ããŒã«ãŒãšããŠãåæ²»çå¹æãè©äŸ¡ããäž
ã§åœ¹ã«ç«ã€ãããããã¹ãŠã以äžã«äŸèšŒããã 以äžã«å ±åãããã¹ããè¡ãå Žåã«å®éã«æ¡çš
ããã奜ãŸããæ æ§ã«ãããŠã¯ã125IâIUdRãåº
質ãšããŠçšããããã奜ãŸããã¢ãã»ã€ã·ã¹ãã
ã®çµæãæ¯çããã³æçµæ¿åºŠã第ïŒè¡šã«èšãã
ãé µçŽ æŽ»æ§ã瀺ããæãè¿ãå è¡æè¡ã«æ¯èŒã
ãŠãæ¬çºææ¹æ³ã®æ床ãåçã«é²æ©ããŠããããš
ã瀺ãã°ã©ãã§ããã 第ïŒïŒ¡ããã³ïŒ¢å³ã¯ãâèå±€ã¯ãããã°ã©ãã«
ãã€ãŠâæ¬çºæã«ãã奜ãŸããåºè³ª125IâIUdR
ã®æŸå°ååŠççŽåºŠã®è²¯èµäžã«ãããæžå°ã瀺ãã°
ã©ãã§ããã 第ïŒå³ã¯ãå éšåºè³ªã³ã³ãããŒã«ïŒå¯Ÿç §ïŒãçš
ããæé µçŽ æŽ»æ§ãåäœã§èšç®ããããšã説æãã
ã°ã©ãã§ããã 第ïŒå³ã¯ãdTk枬å®ã«ãããŠè¡æž äžã®é«æ¿åºŠã®
é»æ¢ç圱é¿ã瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ãç°ãªãèšåºæšæ¬ã«ããããŠã€ãŒã«ã¹
dTkã®å決å®ïŒã¿ã€ãã³ã°ïŒããã°ã©ãã«ãã€ãŠ
瀺ãã 第ïŒå³ã¯ãäŸè¡è ããã³åŠå©Šã«ãããdTk掻æ§
ã®æ£åžžååžã瀺ãå³ã§ããã 第ïŒå³ã¯ãäŒææ§åæ žçæ£è ã®è¡æž äžã§æ¬çºæ
ã«äŸã€ãŠæž¬å®ããdTk掻æ§ããç æ°çºçåŸã®çµé
æéãšé¢é£ã¥ããŠç€ºããå³ã§ããã 第ïŒå³ã¯ãçš®ã ã®ãŠã€ãŒã«ã¹æ§ææçããã€ã³
ãã©ãºãèºçããã³ãªãŠã ç ã«ããã€ãæ£è ã®è¡
æž äžã«èŠåºãããdTk掻æ§ãæããã«ããå³ã§ã
ãã 第ïŒïœããã³ïŒïœå³ã¯ãæ¬çºæã«åŸã€ãŠæž¬å®ã
ãè¡æž dTk掻æ§ãšãNHLæ£è ã®ç æãšã®éã®çž
é¢é¢ä¿ã瀺ãå³ã§ããã 第ïŒïŒïœããã³ïŒïŒïœå³ã¯ãNHLæ£è ã®çå
ã®ç¢ºçãšãæ¬çºæã«åŸã€ãŠæž¬å®ããè¡æž dTkã¬ã
ã«ãšã®é¢ä¿ã瀺ãã 第ïŒïŒããã³ïŒïŒå³ã¯ãçš®ã ã®èšåºççµéã蟿
ã€ãNHLæ£è ã®è¡æž dTkã¬ãã«ã®çµéç 究ã説
æããå³ã§ããã 奜ãŸããæ æ§ã®èª¬æ æ¬çºæã®å¥œãŸããæ æ§ã«ãããŠã¯ãäžèšç·©è¡ç³»
ã¯çŽ150mM以äžãç¹ã«å¥œãŸããã¯çŽ100mMã®æ¿
床ã§ãããç·©è¡æ¶²ã®å¥œãŸããPHã¯6.5ãïŒã®ç¯å²
ã§ãç¹ã«çŽ7.4ã奜ãŸããããã¬ã€ã³é žå¡©ãå«æ
ããªãç·©è¡æ¶²ãåå¿æ§ã«å¯ãã¢ããåºåã¯ç¬¬äžã¢
ããåºãæ¬ ãç·©è¡æ¶²ãç¹ã«ããªã¹âãã¬ãšãŒãã
å®è³ªçã«å«æããªãç·©è¡æ¶²ã§æãè¯ãçµæãåŸã
ããHEPESç·©è¡æ¶²ãç¹ã«å¥œãŸããã åºè³ªã¯æŸå°æ§æšèåãããžã³åæäœãç¹ã«2â²â
ããªãã·âïŒâããã²ã³âãŠãªãžã³ã§ããã¹ã
ã§ããã®å Žåãã®æšèã¯åå¿æ§ããã²ã³åäœå çŽ
ã§ããããšã奜ãŸããã奜ãŸããåºè³ªã¯125Iâ
2â²âããªãã·âïŒâãšãŒããŠãªãžã³ã§ããã奜ãŸ
ããåºè³ªæ¿åºŠã¯ïŒÃ10-8ãïŒÃ10-7ã®ç¯å²å ãç¹
ã«çŽ10-7ïŒã§ããã dTkâ枬å®ã®ããã«å¥œãŸããçé žäŸäžäœã¯
ATPã§ããŠã€ãŒã«ã¹dTk枬å®ã®ããã«å¥œãŸãã
çé žäŸäžäœã¯CTPã§ãããçé žäŸäžäœã®å¥œãŸã
ãæ¿åºŠã¯çŽ10mM以äžãç¹ã«çŽ0.5ã5mMã§ã
ããæ¬æ¥ATPããã³CTPãšåæ§ã®ã¢ã€ãœã¶ã€ã
ç¹ç°æ§ããã€ããšãç¥ãããŠããçé žäŸäžäœãçš
ããŠãããã Mg2+ã¯çé žäŸäžäœãšå°ããšãçã¢ã«æ¿åºŠã§å
åšããã®ã奜ãŸããããžããªã¹ã¬ã€ããŒã«ã®ãã
ãªéå å€ãååšããã®ã奜ãŸããã çé žåçæç©ã¯æ¬æ¥ç¥ãããŠããæ¹æ³ã«ãã€ãŠ
枬å®ã§ããïŒäŸãã°GronowitzãšKallanderïŒ
Infec.Immun.29ïŒ425ïŒ1980åç §ïŒã äŸãã°è¡æž åã¯ç±ç¹åæ³ç©ã®ãããªèšåºæšæ¬ã«
ãããdTk掻æ§ãæ€åºããããã«æ¬çºæã«ããã¢
ãã»ã€ã·ã¹ãã ãé©çšããããšã¯ãæãçš®ã®ãŠã€
ãŒã«ã¹ææçããã³æªæ§è «çã®èšºæã®ããã®æ°ã
ãæ段ããããããåè¿°ããæ¹æ³ã«ããåäžã®
dTkã¢ãã»ã€ã§åŸãããç°åžžãªè¡æž dTkã¬ãã«
ïŒäŸãã°ãïŒ10åäœïŒã¯ãäºåŸèšºæçã«äœ¿çšããå Ž
åãããããããŒã«ãŒã«ãªãããšãå€æãããŸã
åæ§ã«é£ç¶dTkå€ãæªæ§çŸæ£ã®é²è¡åã¯éè¡ãç£
èŠããå Žåã®ããããããŒã«ãŒã«ãªãããšãå€æ
ãããæŽã«ããããã®æ£è ã§ã¯è¡æž dTkã¬ãã«ã
åçºã®ããŒã«ãŒãšããŠãåæ²»çå¹æãè©äŸ¡ããäž
ã§åœ¹ã«ç«ã€ãããããã¹ãŠã以äžã«äŸèšŒããã 以äžã«å ±åãããã¹ããè¡ãå Žåã«å®éã«æ¡çš
ããã奜ãŸããæ æ§ã«ãããŠã¯ã125IâIUdRãåº
質ãšããŠçšããããã奜ãŸããã¢ãã»ã€ã·ã¹ãã
ã®çµæãæ¯çããã³æçµæ¿åºŠã第ïŒè¡šã«èšãã
ãè¡šã
ãè¡šã
ïœ äžã€ã®ïŒåè©Šæã®æ¯çã¯ïŒã¢ãã»ã€æ··åç©
51.5ÎŒãåºè³ªæº¶æ¶²6ÎŒïŒ125IâIUdRã®æçµæ¿
床ïŒÃ10-7ïŒã130ã160CiïŒmMïŒãé µçŽ æº¶æ¶²
ïŒäŸãã°è¡æž ïŒ2.5ÎŒïŒåå¿éå§æã«å ãã
ãïŒãæçµå®¹éã¯60ÎŒãšãªãã ïœ HEPESïŒïŒ®âïŒããããã·ãšãã«ããã©ãž
ã³ïŒ®âïŒâãšã¿ã³ã¹ã«ãã³é ž äžè¬ã«ã51.5ÎŒåå¿æº¶æ¶²ã䜿çšçŽåã«6ÎŒåº
質溶液ãšæ··åããŠãäžã€ã®ïŒåè©Šæã調補ããã
2.5ÎŒé µçŽ æº¶æ¶²ïŒäŸãã°è¡æž è©ŠæïŒã®æ·»å ã«ãã€
ãŠåå¿ãå§ãŸããå šé60ÎŒãšãããã®æšæºå®¹é
ãã25ÎŒã¥ã€ïŒåè©Šæããšããç°ãªãã€ã³ããŠ
ããŒã·ãšã³æéããããŠæ¡åãããæ°çµã®ïŒåè©Š
æããæãå®éšã®ããã®ã¢ãã»ã€æ··æ¶²ã®çµæã¯ã
æšæºæº¶æ¶²äžã®æåã®éã«ãïŒåè©Šæã®æææ°ãä¹
ããããšã«ãã€ãŠèšç®ããããã¢ãã»ã€ã¯37âã§
è¡ãããåå¿éå§ã®åã«ïŒåéå šæåããããã
ãããããããè©Šæãããããã§ã90ã100âã«
ä¿ãããïŒcm2ã®Whatman DEAEâ81çŽçäžã«çœ®
ãããšã«ãã€ãŠãé µçŽ åå¿ã¯çµããçæç©ãåºè³ª
ããåé¢ããããã«ããã®çŽã6mMè»é žã¢ã³ã¢
ããŠã 溶液ã§ïŒåãèžæºæ°Žã§ïŒåãæåŸã«ã¡ã¿ã
ãŒã«ã§æŽããæŽæµã¯ãç£æ°æªæåšã«ãšãã€ããã
ãïŒã®ã¬ã©ã¹å®¹åšäžã§è¡ãããã10ã15æã®å
圢ã®çŽçãéåšã«å ¥ããŠãåæã«åŠçãããã
ã®éåšãïŒåããã«æ°ããæŽæµæ§œã«ç§»ãã®ã§ã
ããæåŸã«ãã®å圢çŽãèªåã¬ã³ãèšæ°ç®¡ã§ã«ãŠ
ã³ãããã dTkã¢ãã»ã€ã«ãããçµæ¥å€åãæé€ãããã
ã«ãåŸãããåå¿é床ãåäœã«èšç®ãçŽãããé µ
çŽ éãå®ããã®ã«åäœã䜿ãçç±ã¯ãåžè²©ã®125I
âIUdRã®çç©åŠç厩å£ãèŠåºãããããšãšé¢é£
ããŠæåã®æŸå°ååŠççŽåºŠã«å€åãããããã§ã
ããçç©åŠç厩å£ã¯ãè©Šææ¯ã«å ããç·æŸå°èœ
ããé µçŽ æŽ»æ§ã®èšç®ã«ç¡é¢ä¿ãªãã®ã«ããŠããŸ
ãã第ïŒå³ã¯ãäºåã³ãŒãã€ã³ã°ããã·ãªã«ã²ã«
ãã¬ãŒãïŒMerck 60F254ïŒãçšããŠè¡ã€ãèå±€
ã¯ãããã°ã©ãã€ãŒã«ãããåžè²©ã®125IâIUdR
ãããã®åé¢ã瀺ãã溶åºæ¶²ãšããŠ15ïŒ ã¡ã¿ããŒ
ã«ã85ïŒ ã¯ãããã«ã ãçšãããïŒå ¥ææ¥ã«ã
ããæ§ç¶ãæŸå°ååŠççŽåºŠ62ïŒ ã瀺ããïŒ150
æ¥å·èµåº«ã«è²¯èµåŸã®åäžãããã補é æ¥è ã®äž»åŒµ
ã§ã¯ãæåã®æŸå°ååŠçŽåºŠã¯ïŒ90ïŒ ã§ããããã®
代ããææåæ§æŸå°èœã枬å®ããçç©åŠçå éšã³
ã³ãããŒã«ïŒå¯Ÿç §ïŒãåã¢ãã»ã€ã«å«ããããã®
å¯Ÿç §ã¯HSV2ådTkã100åãå€ãå«ããã®ã§ã
ã€ãŠã倧èŠæš¡ãªåºè³ªç²æãæãããïŒæéã¢ãã»
ã€ã«ãããŠããã®å¯Ÿç §ã«ããæ¿å ¥ãããæŸå°èœã®
éã¯å®å šãª125IâIUdRã®çŽ85ïŒ ã§ããããšãã
ãã€ãïŒèå±€ã¯ãããã°ã©ãã€ãŒããèšç®ããŠïŒã
çç©åŠçå¯Ÿç §ã§èŠåºããããã®ã¬ãã«ïŒ85ïŒ ïŒã
èæ ®ããŠãé µçŽ ïŒåäœã¯ãïŒèšèŒããæ¡ä»¶äžã§ïŒ
ïŒæéã«ã€ãåºè³ª4.3Ã10-15ã¢ã«ãå€æããé µçŽ
éãšãªããåäœãšãæŠç®ã¢ã«ã»ã¿ãŒã³ãªãŒããŒãš
ã®éã®ãã®é¢ä¿ã¯ãéåžžçšããããåäœå çŽ éã®
å ŽåãïŒåäœãå®éäžçŽ1000cpmãšããŠãããã
ããããã«éžæãããïŒç¬¬ïŒè¡šåç §ïŒããã®çç©
åŠçåäœå çŽ å¯Ÿç §ããè©Šéšè©Šæãšåæ§ãªæ¹æ³ã§åŠ
çããŠçšããå Žåã®ããäžã€ã®å©ç¹ã¯ãçç£ç©å
åçã®å€åã«ãããããåŸãåäœã®å€åãåé¿ã
ããããšã§ãããåäœèšç®ã®æé ã¯ç¬¬ïŒå³ã«äŸç€º
ãããè©ŠæïŒâââââïŒããã³å¯Ÿç §ïŒââ³ââ³
âïŒäž¡æ¹ã®å€ã瀺ããã¯å éšå¯Ÿç §ã®å€ãcpmã§
ãããããŠããïŒããã¯å©çšå¯èœã®ç·æŸå°æ§æšè
ååºè³ªã«æ¯äŸãããã¯è¢«éšè©Šæã«ããçæãã
ç£ç©ã®æ°å€ãcpmïŒhourã§ããããããã®ã§ã
ãã åäœïŒïŒµïŒïŒïŒ¢ÃïŒïŒ³ïŒÃïœïŒïŒ¡Ã5.3Ã10-15ããã
ã§ïŒïŒ³ïŒã¯ åºè³ªæ¿åºŠïŒïŒïŒãïœã¯è©Šæã®éïŒïŒã§ããã è¡æž ïœïŒŽïœæŽ»æ§ã®æž¬å® è¡æž dTkã®å®éããã¯ãã¿ã€ã¿ãŒã»ãã¬ãŒãã§
è¡ãªã€ãã20è¡æž è©Šææ¯ã«ãããã¯ã°ã©ãŠã³ã察
ç §ãšå éšåºè³ªå¯Ÿç §ïŒäžèšåç §ïŒãå«ãŸãããã®äž
çµããŠãããããŠåŠçãããçšããè¡æž è©Šæã®é
ã¯æçµå®¹é120ÎŒããã5ÎŒïŒåã¯ãã以äžïŒ
ã§ãã€ãïŒãã以äžã®è¡æž ã¯é»æ¢çã«åãããç¥
ããªãã第ïŒå³åç §ã120ååŸã«ãµã³ããªã³ã°ã
è¡ã€ãŠdTk掻æ§ã枬å®ãããé µçŽ æŽ»æ§ããè©Šæ
60ÎŒãããã®è¡æž æ¿åºŠã«å¯ŸããŠããããããã
ïŒâââïŒïŒNHLã«çœ¹ã€ãåäœããã®è¡æž ãïŒâ³â
â³ïŒïŒæŽ»æ§CLLã«ããã€ãåäœããã®è¡æž ãäžèš
ã®é»æ¢ç圱é¿ã¯ãå€åãäŸãã°ãããžã³ããããž
ã³äžçé žå¡©ã®ãããªããã¯ã¬ãªããåã¯ãã¯ã¬ãª
ã·ãã®ååšãåã¯æãè¡æž äžã«ã¯ååšããå解çš
é µçŽ ã«ãããã®ã§ãããã60ååŸãš120ååŸã«äº
éã«è©Šæãæ¡åãããããã¯ã°ã©ãŠã³ããè£æ£ã
ãåŸãïŒæéããã³25Ό詊æã«ã€ããŠã®å¹å°ã¿
ãŒã³ãªãŒããŒããåäºåè©Šæããå¥å¥ã«èšç®ã
ãããããã60åããã³120åãµã³ããªã³ã°ã®å¹³
åé床å€ã枬å®ããå€åãïŒ20ïŒ ã§ãã€ãå Žåã¯
ãã®å¹³åé床å€ããã®åŸã®èšç®ã«çšããã é«æ¶²äžã®dTk掻æ§ã®æž¬å® æ¬è³ªçã«ã¯è¡æž ã®å Ž
åãšåãæ¹æ³ãçšããã125IâIUdRã®æ¯æŸå°èœã
çŽ320CiïŒmMã«å¢å ããããé µçŽ æž¬å®ã®åã«é«
液ãæ¿çž®ããŠãããã dTkã¢ã€ãœã¶ã€ã ã®å®æ§è©Šéš dTk掻æ§ãå«
ããäŸãã°å°æ°Žç±æ¶²ãè¡æž ã®ãããªèšåºæšæ¬ãã
ã¢ã€ãœã¶ã€ã ã«ç¹ç°çãªdTké»æ¢æäœãšå ±ã«ãã
ãããã€ã³ããŠããŒãããæ®ãã®é µçŽ 掻æ§ãäžè¿°
ã®æ¹æ³ã«ãã€ãŠæž¬å®ãããã¢ãã»ã€æ··æ¶²äžã®
ATPãCTPã«ä»£ããããã®çµædTkâ掻æ§ã¯
é€ããããè©Šéšãã¹ãæšæ¬ãåå¿æº¶æ¶²ã§æ®µéçäº
åçšéãè¡ãïŒæ®éã¯ïŒïŒïŒã§éå§ããïŒããã
ãŠçšé液ãã15ÎŒã¥ã€ããã¯ãã¿ã€ã¿ãŒãã¬ãŒ
ãã®ïŒã€ã®å¹ã¿ã«ç§»ããããããŠåäžçšéã®ïŒæ€
äœãïŒçµãšãªãã ãããããçšéããVZV dTkâé»æ¢è¡æž ïŒ25
mlïŒãïŒã€ã®å¹ã¿ã«å ããHSV ïŒådTké»æ¢è¡
æž ãïŒçªç®ã®å¹ã¿ã«ãHSV2ådTké»æ¢è¡æž ãïŒ
çªç®ã®å¹ã¿ã«ããã€ãã¹è¡æž ãïŒçªç®ã®å¹ã¿ã«å
ããããã®æ··åç©ã37âã§90åéã€ã³ããŠããŒã
ããé µçŽ âæäœåå¿ãè¡ãããããã®åŸæ®çé µçŽ
掻æ§ã枬å®ãããåºè³ªæº¶æ¶²6ÎŒããã³åå¿æº¶æ¶²
14ÎŒããæãæ··å液20ÎŒãå ããããšã«ãã
åå¿ã¯éå§ãããåçšéæ¯ã«ç°ãªãæäœã®ååšäž
ã§åŸãããæ°å€ãããã€ãã¹è¡æž ã§åŸãããæ°å€
ã®ããŒã»ã³ããŒãžãšããŠèšç®ãçŽããããã®ãã
ãªæ®çé µçŽ æŽ»æ§ããæšæ¬ã®log2çšéã«å¯ŸããŠãã
ããããäŸã第ïŒå³ã«ç€ºãïŒããã§ã¯æâVZV
dTkè¡æž ïŒâ³ââ³ïŒãæâHSV ïŒådTkè¡æž
ïŒâââïŒããã³æâHSV ïŒåè¡æž ïŒâââïŒ
ãšå ±ã«ã€ã³ããŠããŒã·ãšã³ããåŸã®æ®ç掻æ§ãšã
ãã€ãã¹è¡æž ãšå ±ã«ã€ã³ããŠããŒã·ãšã³ããå¯Ÿç §
ãšã®æ¯ãã次ã®è©Šæã®çš®ã ã®çšéã«å¯ŸããŠããã
ãããïŒïŒ¡ïŒHSV ïŒåææçã«ããã€ãåºäœã
ãã®å°æ°Žç±æ¶²ïŒïŒ¢ïŒVZVææçã«ããã€ãåäœ
ããã®å°æ°Žç±æ¶²ïŒHSV ïŒåææçã«ããã€ãå
äœããã®å°æ°Žç±æ¶²ïŒVZVææçã«ããã€ãåäœ
ããã®è¡æž ãé»æ¢ãã¿ãŒã³ãããdTkã®åã容æ
ã«å®ããããïŒä»¥äžã®ç¬¬ïŒè¡šãåç §ïŒã
51.5ÎŒãåºè³ªæº¶æ¶²6ÎŒïŒ125IâIUdRã®æçµæ¿
床ïŒÃ10-7ïŒã130ã160CiïŒmMïŒãé µçŽ æº¶æ¶²
ïŒäŸãã°è¡æž ïŒ2.5ÎŒïŒåå¿éå§æã«å ãã
ãïŒãæçµå®¹éã¯60ÎŒãšãªãã ïœ HEPESïŒïŒ®âïŒããããã·ãšãã«ããã©ãž
ã³ïŒ®âïŒâãšã¿ã³ã¹ã«ãã³é ž äžè¬ã«ã51.5ÎŒåå¿æº¶æ¶²ã䜿çšçŽåã«6ÎŒåº
質溶液ãšæ··åããŠãäžã€ã®ïŒåè©Šæã調補ããã
2.5ÎŒé µçŽ æº¶æ¶²ïŒäŸãã°è¡æž è©ŠæïŒã®æ·»å ã«ãã€
ãŠåå¿ãå§ãŸããå šé60ÎŒãšãããã®æšæºå®¹é
ãã25ÎŒã¥ã€ïŒåè©Šæããšããç°ãªãã€ã³ããŠ
ããŒã·ãšã³æéããããŠæ¡åãããæ°çµã®ïŒåè©Š
æããæãå®éšã®ããã®ã¢ãã»ã€æ··æ¶²ã®çµæã¯ã
æšæºæº¶æ¶²äžã®æåã®éã«ãïŒåè©Šæã®æææ°ãä¹
ããããšã«ãã€ãŠèšç®ããããã¢ãã»ã€ã¯37âã§
è¡ãããåå¿éå§ã®åã«ïŒåéå šæåããããã
ãããããããè©Šæãããããã§ã90ã100âã«
ä¿ãããïŒcm2ã®Whatman DEAEâ81çŽçäžã«çœ®
ãããšã«ãã€ãŠãé µçŽ åå¿ã¯çµããçæç©ãåºè³ª
ããåé¢ããããã«ããã®çŽã6mMè»é žã¢ã³ã¢
ããŠã 溶液ã§ïŒåãèžæºæ°Žã§ïŒåãæåŸã«ã¡ã¿ã
ãŒã«ã§æŽããæŽæµã¯ãç£æ°æªæåšã«ãšãã€ããã
ãïŒã®ã¬ã©ã¹å®¹åšäžã§è¡ãããã10ã15æã®å
圢ã®çŽçãéåšã«å ¥ããŠãåæã«åŠçãããã
ã®éåšãïŒåããã«æ°ããæŽæµæ§œã«ç§»ãã®ã§ã
ããæåŸã«ãã®å圢çŽãèªåã¬ã³ãèšæ°ç®¡ã§ã«ãŠ
ã³ãããã dTkã¢ãã»ã€ã«ãããçµæ¥å€åãæé€ãããã
ã«ãåŸãããåå¿é床ãåäœã«èšç®ãçŽãããé µ
çŽ éãå®ããã®ã«åäœã䜿ãçç±ã¯ãåžè²©ã®125I
âIUdRã®çç©åŠç厩å£ãèŠåºãããããšãšé¢é£
ããŠæåã®æŸå°ååŠççŽåºŠã«å€åãããããã§ã
ããçç©åŠç厩å£ã¯ãè©Šææ¯ã«å ããç·æŸå°èœ
ããé µçŽ æŽ»æ§ã®èšç®ã«ç¡é¢ä¿ãªãã®ã«ããŠããŸ
ãã第ïŒå³ã¯ãäºåã³ãŒãã€ã³ã°ããã·ãªã«ã²ã«
ãã¬ãŒãïŒMerck 60F254ïŒãçšããŠè¡ã€ãèå±€
ã¯ãããã°ã©ãã€ãŒã«ãããåžè²©ã®125IâIUdR
ãããã®åé¢ã瀺ãã溶åºæ¶²ãšããŠ15ïŒ ã¡ã¿ããŒ
ã«ã85ïŒ ã¯ãããã«ã ãçšãããïŒå ¥ææ¥ã«ã
ããæ§ç¶ãæŸå°ååŠççŽåºŠ62ïŒ ã瀺ããïŒ150
æ¥å·èµåº«ã«è²¯èµåŸã®åäžãããã補é æ¥è ã®äž»åŒµ
ã§ã¯ãæåã®æŸå°ååŠçŽåºŠã¯ïŒ90ïŒ ã§ããããã®
代ããææåæ§æŸå°èœã枬å®ããçç©åŠçå éšã³
ã³ãããŒã«ïŒå¯Ÿç §ïŒãåã¢ãã»ã€ã«å«ããããã®
å¯Ÿç §ã¯HSV2ådTkã100åãå€ãå«ããã®ã§ã
ã€ãŠã倧èŠæš¡ãªåºè³ªç²æãæãããïŒæéã¢ãã»
ã€ã«ãããŠããã®å¯Ÿç §ã«ããæ¿å ¥ãããæŸå°èœã®
éã¯å®å šãª125IâIUdRã®çŽ85ïŒ ã§ããããšãã
ãã€ãïŒèå±€ã¯ãããã°ã©ãã€ãŒããèšç®ããŠïŒã
çç©åŠçå¯Ÿç §ã§èŠåºããããã®ã¬ãã«ïŒ85ïŒ ïŒã
èæ ®ããŠãé µçŽ ïŒåäœã¯ãïŒèšèŒããæ¡ä»¶äžã§ïŒ
ïŒæéã«ã€ãåºè³ª4.3Ã10-15ã¢ã«ãå€æããé µçŽ
éãšãªããåäœãšãæŠç®ã¢ã«ã»ã¿ãŒã³ãªãŒããŒãš
ã®éã®ãã®é¢ä¿ã¯ãéåžžçšããããåäœå çŽ éã®
å ŽåãïŒåäœãå®éäžçŽ1000cpmãšããŠãããã
ããããã«éžæãããïŒç¬¬ïŒè¡šåç §ïŒããã®çç©
åŠçåäœå çŽ å¯Ÿç §ããè©Šéšè©Šæãšåæ§ãªæ¹æ³ã§åŠ
çããŠçšããå Žåã®ããäžã€ã®å©ç¹ã¯ãçç£ç©å
åçã®å€åã«ãããããåŸãåäœã®å€åãåé¿ã
ããããšã§ãããåäœèšç®ã®æé ã¯ç¬¬ïŒå³ã«äŸç€º
ãããè©ŠæïŒâââââïŒããã³å¯Ÿç §ïŒââ³ââ³
âïŒäž¡æ¹ã®å€ã瀺ããã¯å éšå¯Ÿç §ã®å€ãcpmã§
ãããããŠããïŒããã¯å©çšå¯èœã®ç·æŸå°æ§æšè
ååºè³ªã«æ¯äŸãããã¯è¢«éšè©Šæã«ããçæãã
ç£ç©ã®æ°å€ãcpmïŒhourã§ããããããã®ã§ã
ãã åäœïŒïŒµïŒïŒïŒ¢ÃïŒïŒ³ïŒÃïœïŒïŒ¡Ã5.3Ã10-15ããã
ã§ïŒïŒ³ïŒã¯ åºè³ªæ¿åºŠïŒïŒïŒãïœã¯è©Šæã®éïŒïŒã§ããã è¡æž ïœïŒŽïœæŽ»æ§ã®æž¬å® è¡æž dTkã®å®éããã¯ãã¿ã€ã¿ãŒã»ãã¬ãŒãã§
è¡ãªã€ãã20è¡æž è©Šææ¯ã«ãããã¯ã°ã©ãŠã³ã察
ç §ãšå éšåºè³ªå¯Ÿç §ïŒäžèšåç §ïŒãå«ãŸãããã®äž
çµããŠãããããŠåŠçãããçšããè¡æž è©Šæã®é
ã¯æçµå®¹é120ÎŒããã5ÎŒïŒåã¯ãã以äžïŒ
ã§ãã€ãïŒãã以äžã®è¡æž ã¯é»æ¢çã«åãããç¥
ããªãã第ïŒå³åç §ã120ååŸã«ãµã³ããªã³ã°ã
è¡ã€ãŠdTk掻æ§ã枬å®ãããé µçŽ æŽ»æ§ããè©Šæ
60ÎŒãããã®è¡æž æ¿åºŠã«å¯ŸããŠããããããã
ïŒâââïŒïŒNHLã«çœ¹ã€ãåäœããã®è¡æž ãïŒâ³â
â³ïŒïŒæŽ»æ§CLLã«ããã€ãåäœããã®è¡æž ãäžèš
ã®é»æ¢ç圱é¿ã¯ãå€åãäŸãã°ãããžã³ããããž
ã³äžçé žå¡©ã®ãããªããã¯ã¬ãªããåã¯ãã¯ã¬ãª
ã·ãã®ååšãåã¯æãè¡æž äžã«ã¯ååšããå解çš
é µçŽ ã«ãããã®ã§ãããã60ååŸãš120ååŸã«äº
éã«è©Šæãæ¡åãããããã¯ã°ã©ãŠã³ããè£æ£ã
ãåŸãïŒæéããã³25Ό詊æã«ã€ããŠã®å¹å°ã¿
ãŒã³ãªãŒããŒããåäºåè©Šæããå¥å¥ã«èšç®ã
ãããããã60åããã³120åãµã³ããªã³ã°ã®å¹³
åé床å€ã枬å®ããå€åãïŒ20ïŒ ã§ãã€ãå Žåã¯
ãã®å¹³åé床å€ããã®åŸã®èšç®ã«çšããã é«æ¶²äžã®dTk掻æ§ã®æž¬å® æ¬è³ªçã«ã¯è¡æž ã®å Ž
åãšåãæ¹æ³ãçšããã125IâIUdRã®æ¯æŸå°èœã
çŽ320CiïŒmMã«å¢å ããããé µçŽ æž¬å®ã®åã«é«
液ãæ¿çž®ããŠãããã dTkã¢ã€ãœã¶ã€ã ã®å®æ§è©Šéš dTk掻æ§ãå«
ããäŸãã°å°æ°Žç±æ¶²ãè¡æž ã®ãããªèšåºæšæ¬ãã
ã¢ã€ãœã¶ã€ã ã«ç¹ç°çãªdTké»æ¢æäœãšå ±ã«ãã
ãããã€ã³ããŠããŒãããæ®ãã®é µçŽ 掻æ§ãäžè¿°
ã®æ¹æ³ã«ãã€ãŠæž¬å®ãããã¢ãã»ã€æ··æ¶²äžã®
ATPãCTPã«ä»£ããããã®çµædTkâ掻æ§ã¯
é€ããããè©Šéšãã¹ãæšæ¬ãåå¿æº¶æ¶²ã§æ®µéçäº
åçšéãè¡ãïŒæ®éã¯ïŒïŒïŒã§éå§ããïŒããã
ãŠçšé液ãã15ÎŒã¥ã€ããã¯ãã¿ã€ã¿ãŒãã¬ãŒ
ãã®ïŒã€ã®å¹ã¿ã«ç§»ããããããŠåäžçšéã®ïŒæ€
äœãïŒçµãšãªãã ãããããçšéããVZV dTkâé»æ¢è¡æž ïŒ25
mlïŒãïŒã€ã®å¹ã¿ã«å ããHSV ïŒådTké»æ¢è¡
æž ãïŒçªç®ã®å¹ã¿ã«ãHSV2ådTké»æ¢è¡æž ãïŒ
çªç®ã®å¹ã¿ã«ããã€ãã¹è¡æž ãïŒçªç®ã®å¹ã¿ã«å
ããããã®æ··åç©ã37âã§90åéã€ã³ããŠããŒã
ããé µçŽ âæäœåå¿ãè¡ãããããã®åŸæ®çé µçŽ
掻æ§ã枬å®ãããåºè³ªæº¶æ¶²6ÎŒããã³åå¿æº¶æ¶²
14ÎŒããæãæ··å液20ÎŒãå ããããšã«ãã
åå¿ã¯éå§ãããåçšéæ¯ã«ç°ãªãæäœã®ååšäž
ã§åŸãããæ°å€ãããã€ãã¹è¡æž ã§åŸãããæ°å€
ã®ããŒã»ã³ããŒãžãšããŠèšç®ãçŽããããã®ãã
ãªæ®çé µçŽ æŽ»æ§ããæšæ¬ã®log2çšéã«å¯ŸããŠãã
ããããäŸã第ïŒå³ã«ç€ºãïŒããã§ã¯æâVZV
dTkè¡æž ïŒâ³ââ³ïŒãæâHSV ïŒådTkè¡æž
ïŒâââïŒããã³æâHSV ïŒåè¡æž ïŒâââïŒ
ãšå ±ã«ã€ã³ããŠããŒã·ãšã³ããåŸã®æ®ç掻æ§ãšã
ãã€ãã¹è¡æž ãšå ±ã«ã€ã³ããŠããŒã·ãšã³ããå¯Ÿç §
ãšã®æ¯ãã次ã®è©Šæã®çš®ã ã®çšéã«å¯ŸããŠããã
ãããïŒïŒ¡ïŒHSV ïŒåææçã«ããã€ãåºäœã
ãã®å°æ°Žç±æ¶²ïŒïŒ¢ïŒVZVææçã«ããã€ãåäœ
ããã®å°æ°Žç±æ¶²ïŒHSV ïŒåææçã«ããã€ãå
äœããã®å°æ°Žç±æ¶²ïŒVZVææçã«ããã€ãåäœ
ããã®è¡æž ãé»æ¢ãã¿ãŒã³ãããdTkã®åã容æ
ã«å®ããããïŒä»¥äžã®ç¬¬ïŒè¡šãåç §ïŒã
ãè¡šã
ããããŠãæ¬çºæã®éèŠãªç¹åŸŽã®äžã€ã¯ãåç
ã«å¢å ããæ€åºæ床ã§ããããã®ãããã§ç¬¬ïŒå³
ããå€ãããã«ïŒç¬¬ïŒå³ã¯99人ã®äŸè¡è ã®è¡æž äž
ã«èŠåºãããdTk掻æ§ã®ååžïŒçœæ±ïŒãšãïŒã±æ
以å ã®åŠå©Š22人ã®è¡æž äžã®ããã®ååžïŒæç·æ±ïŒ
ãšã瀺ãïŒãå¥åžžè ã®è¡æž äžã®æ£åžžãªdTkâã¬
ãã«ã®æž¬å®ããå¯èœãšãªããå¹³åå€ã¯2.4åäœïŒ
ÎŒãæšæºåå·®ã¯1.25ã§ããã æææ§çŸæ£ã«ããã€ãåäœããåŸãè¡æž è©Šæã
ç 究ããããšã«ãã€ãŠãæãçš®ã®ãŠã€ãŒã«ã¹æ§çŸ
æ£äŸãã°äŒæåæ žçã颚ç¹âã麻ç¹âãŠã€ãŒã«ã¹
ææçã®æ¥æ§æã«ãããæ£è ã®è¡æž äždTkã¬ãã«
ã¯10ã40åäžæããŠããããšãçºèŠãããã第ïŒ
å³ã¯ãäŒææ§åæ žçæ£è ã®è¡æž äžã«çæããdTk
掻æ§ïŒÎŒãããã®ç æ°ã®çºçåŸã®æéçµéãšé¢
é£ã¥ããŠç€ºãããã®ã§ãããåäžæåãä»ããâ
å°ã¯åäžæ£è ããã®è¡æž ã瀺ããç¹ç·ã¯å¥åžžè ã®
æ£åžžå€ã瀺ãã第ïŒå³ã¯çš®ã ã®ãŠã€ãŒã«ã¹ææ
çããã€ã³ãã©ãºãèºçãããã³ãªãŠã ç ã«ãã
ã€ãæ£è ã®æ¥æ§æïŒâïŒããã³å埩æïŒâïŒã®è¡
æž äžã«èŠåºãããdTk掻æ§ïŒÎŒã瀺ããç¹ç·
ã¯ãå¥åžžè ã®æ£åžžå€ã®ïŒåã®æ°å€ã瀺ãã ãã®çµæã«ãããšããã«ãã¹ãŠã€ãŒã«ã¹ã«é¢ã
ãŠã¯åææçã®ããã«è¡æž dTk掻æ§ãäžæããã
ãšã瀺ããããä»ã®ææçã«é¢ããŠã¯ããã®çµæ
ãšããŠãããdTk掻æ§ã®äžæïŒïŒ10åäœïŒã¯èŠåº
ãããªãã€ãïŒç¬¬ïŒå³ïŒãèŠåºãããè¡æž 掻æ§ã
ç¹åŸŽã¥ãããšããããŸã§ã«æ°Žçâ垯ç¶ç±ç¹ãŠã€ãŒ
ã«ã¹ïŒVZVïŒâç¹ç°çâdTkïŒç¬¬ïŒè¡šïŒããã³çŽ°
èdTkâã®ååšã蚌æããããæ¬çºææ¹æ³ã¯ã
ææçãéãã«èšºæããããã«å°æ°Žç±æ¶²äžã«ååš
ãããŠã€ãŒã«ã¹ç¹ç°çâdTkã決å®ããããã«çš
ããããšãã§ããããšã蚌æãããïŒç¬¬ïŒè¡šïŒã
ãŠã€ãŒã«ã¹ææçãšé¢é£ããŠèŠåºããããã¹ãŠã®
è¡æž dTk掻æ§ã¯ãåŸã ã«æ¶å€±ããïŒãïŒé±é以å
ã«æ£åžžã¬ãã«ã«éããã æªæ§çŸæ£æ£è ã«é¢ããŠã¯ãæ¬çºæã«äŸãã¢ãã»
ã€æ³ãçšããéãããç 究ã®çµæããªã³ãçâå¢
æ®ç³»ã«èµ·å ããæªæ§è «çã«ããã€ãŠããæ£è ã®ã¿
ãªããããã®ä»ã®çŽ°èã®æªæ§è «çã«ãããããªã³
ãçå¢æ®ç³»ã«è»¢ç§»ããæ£è ã«ãããŠãè¡æž dTkã¬
ãã«ã®äžæã蚌æãããïŒç¬¬ïŒè¡šåç §ïŒã éããžãã³æ§ãªã³ãè «ïŒNHLïŒãããžãã³ç
ïŒHDïŒãæ ¢æ§æŽ»æ§åãªã³ãæ§çœè¡ç ïŒCLLïŒãã
ã³éªšé«è «ã®ãããªããªã³ãçå¢æ®çã«ããã€ãŠã
ãæ£è ãããååã«ç¢ºèªããã倧éã®è¡æž è©Šæã
åŸãŠããããçšããŠå€§èŠæš¡ãªç 究ãè¡ã€ãã
NHL矀ã®è©³çŽ°ãªçµæã¯æ¬¡ã®ããã§ãã€ããïŒæ£åžž
ãªè¡æž dTkã¬ãã«ãšãçš®ã ã®çšåºŠã«äžæããdTk
ã¬ãã«ãçºèŠãããããããã®dTkã¬ãã«ã¯ç æ°
ãšé¢é£ããŠããïŒç¬¬ïŒå³åç §ããã®å³ã¯ãæªåŠçœ®
ã®NHLæ£è 155人ã®è¡æž äždTkãç æãšé¢é£ã¥ã
ãŠç€ºãïŒãå³ã¡ç æ°ãé²è¡ããã°ããçšdTkå€ã¯
é«ããªãã
ã«å¢å ããæ€åºæ床ã§ããããã®ãããã§ç¬¬ïŒå³
ããå€ãããã«ïŒç¬¬ïŒå³ã¯99人ã®äŸè¡è ã®è¡æž äž
ã«èŠåºãããdTk掻æ§ã®ååžïŒçœæ±ïŒãšãïŒã±æ
以å ã®åŠå©Š22人ã®è¡æž äžã®ããã®ååžïŒæç·æ±ïŒ
ãšã瀺ãïŒãå¥åžžè ã®è¡æž äžã®æ£åžžãªdTkâã¬
ãã«ã®æž¬å®ããå¯èœãšãªããå¹³åå€ã¯2.4åäœïŒ
ÎŒãæšæºåå·®ã¯1.25ã§ããã æææ§çŸæ£ã«ããã€ãåäœããåŸãè¡æž è©Šæã
ç 究ããããšã«ãã€ãŠãæãçš®ã®ãŠã€ãŒã«ã¹æ§çŸ
æ£äŸãã°äŒæåæ žçã颚ç¹âã麻ç¹âãŠã€ãŒã«ã¹
ææçã®æ¥æ§æã«ãããæ£è ã®è¡æž äždTkã¬ãã«
ã¯10ã40åäžæããŠããããšãçºèŠãããã第ïŒ
å³ã¯ãäŒææ§åæ žçæ£è ã®è¡æž äžã«çæããdTk
掻æ§ïŒÎŒãããã®ç æ°ã®çºçåŸã®æéçµéãšé¢
é£ã¥ããŠç€ºãããã®ã§ãããåäžæåãä»ããâ
å°ã¯åäžæ£è ããã®è¡æž ã瀺ããç¹ç·ã¯å¥åžžè ã®
æ£åžžå€ã瀺ãã第ïŒå³ã¯çš®ã ã®ãŠã€ãŒã«ã¹ææ
çããã€ã³ãã©ãºãèºçãããã³ãªãŠã ç ã«ãã
ã€ãæ£è ã®æ¥æ§æïŒâïŒããã³å埩æïŒâïŒã®è¡
æž äžã«èŠåºãããdTk掻æ§ïŒÎŒã瀺ããç¹ç·
ã¯ãå¥åžžè ã®æ£åžžå€ã®ïŒåã®æ°å€ã瀺ãã ãã®çµæã«ãããšããã«ãã¹ãŠã€ãŒã«ã¹ã«é¢ã
ãŠã¯åææçã®ããã«è¡æž dTk掻æ§ãäžæããã
ãšã瀺ããããä»ã®ææçã«é¢ããŠã¯ããã®çµæ
ãšããŠãããdTk掻æ§ã®äžæïŒïŒ10åäœïŒã¯èŠåº
ãããªãã€ãïŒç¬¬ïŒå³ïŒãèŠåºãããè¡æž 掻æ§ã
ç¹åŸŽã¥ãããšããããŸã§ã«æ°Žçâ垯ç¶ç±ç¹ãŠã€ãŒ
ã«ã¹ïŒVZVïŒâç¹ç°çâdTkïŒç¬¬ïŒè¡šïŒããã³çŽ°
èdTkâã®ååšã蚌æããããæ¬çºææ¹æ³ã¯ã
ææçãéãã«èšºæããããã«å°æ°Žç±æ¶²äžã«ååš
ãããŠã€ãŒã«ã¹ç¹ç°çâdTkã決å®ããããã«çš
ããããšãã§ããããšã蚌æãããïŒç¬¬ïŒè¡šïŒã
ãŠã€ãŒã«ã¹ææçãšé¢é£ããŠèŠåºããããã¹ãŠã®
è¡æž dTk掻æ§ã¯ãåŸã ã«æ¶å€±ããïŒãïŒé±é以å
ã«æ£åžžã¬ãã«ã«éããã æªæ§çŸæ£æ£è ã«é¢ããŠã¯ãæ¬çºæã«äŸãã¢ãã»
ã€æ³ãçšããéãããç 究ã®çµæããªã³ãçâå¢
æ®ç³»ã«èµ·å ããæªæ§è «çã«ããã€ãŠããæ£è ã®ã¿
ãªããããã®ä»ã®çŽ°èã®æªæ§è «çã«ãããããªã³
ãçå¢æ®ç³»ã«è»¢ç§»ããæ£è ã«ãããŠãè¡æž dTkã¬
ãã«ã®äžæã蚌æãããïŒç¬¬ïŒè¡šåç §ïŒã éããžãã³æ§ãªã³ãè «ïŒNHLïŒãããžãã³ç
ïŒHDïŒãæ ¢æ§æŽ»æ§åãªã³ãæ§çœè¡ç ïŒCLLïŒãã
ã³éªšé«è «ã®ãããªããªã³ãçå¢æ®çã«ããã€ãŠã
ãæ£è ãããååã«ç¢ºèªããã倧éã®è¡æž è©Šæã
åŸãŠããããçšããŠå€§èŠæš¡ãªç 究ãè¡ã€ãã
NHL矀ã®è©³çŽ°ãªçµæã¯æ¬¡ã®ããã§ãã€ããïŒæ£åžž
ãªè¡æž dTkã¬ãã«ãšãçš®ã ã®çšåºŠã«äžæããdTk
ã¬ãã«ãçºèŠãããããããã®dTkã¬ãã«ã¯ç æ°
ãšé¢é£ããŠããïŒç¬¬ïŒå³åç §ããã®å³ã¯ãæªåŠçœ®
ã®NHLæ£è 155人ã®è¡æž äždTkãç æãšé¢é£ã¥ã
ãŠç€ºãïŒãå³ã¡ç æ°ãé²è¡ããã°ããçšdTkå€ã¯
é«ããªãã
ãè¡šã
ãè¡šã
dTkã¬ãã«ãè
«ç现èã®æªæ§åãšé¢é£ã¥ããŠèŠ
ãæïŒããŒã«ã»ã·ã¹ãã ã«ããåé¡ïŒãé«ãdTk
ã¬ãã«ãšæªæ§åã®éã«ã¯ååãªçžé¢é¢ä¿ãèªãã
ãããïŒç¬¬ïŒå³åç §ãïŒæã«åããããæªæ§è «ç
ã®ç¬¬ãæã®NHLæ£è 101人ã«ãããè¡æž dTk
ã瀺ãïŒã æ¬çºæã«ããã¢ãã»ã€æ³ãäºåŸãç¥ãç®çã®ã
ãã«äœ¿çšãåŸãããšã蚌æããããããã¯ã枬å®
ããdTkå€ãïŒ10åäœã§ããããïŒ10åäœã§ãã
ãã«ãã€ãŠåé¡ããæ£è 矀ã®éã§ãçåæéã«é«
床ã«ææãªå·®ããããããããã§ããã第ïŒïŒïœ
å³ã¯ãããããã枬å®ããè¡æž dTkãïŒ10åäœ
ïŒâââââïŒïœïŒ50ïŒåã¯ïŒ10åäœïŒââââ
âïŒïœïŒ51ïŒã瀺ãããæã®NHLæ£è ã®ç
å確çã瀺ããã«ãã³å ã®æ°åã¯ã32ã±æåŸã®èŠ³
å¯æã«çãæ®ã€ãŠãã人æ°ã瀺ãã第ïŒïŒïœå³
ã¯ãâé«åºŠã«âæªæ§åããè «çããã€ããæ
ã®NHLæ£è ã«ã€ããŠã®çå確çã瀺ããããã
ãã枬å®ããdTkã¬ãã«ïŒïŒ10åäœïŒââââ
âïŒïœïŒ11ããã³ïŒ10åäœïŒâââââïŒïœïŒ
27ïŒãã«ãã³å ã®æ°åã¯32ã±æåŸã®èŠ³å¯æã«æ®ã€
ãŠãã人æ°ã§ããã æŽã«ãNHLæ£è ã®è¡æž dTkã¬ãã«ã®çµæç 究
ã¯ãç æ°ã®å€åã«çžé¢ããå€åãããããããå³
ã¡ç æ°ã®å埩ã§ãã®ã¬ãã«ã¯äœããªããç æ°ã®äº¢
é²ã§é«ããªããå®åžžç¶æ ã§ã¯å€åããªãã第ïŒïŒ
å³ã®ïŒ¡ã¯ã亢é²æã®ç æ°ã®ïŒæ£è ã®è¡æž dTkã¬ã
ã«æž¬å®å€ã®å€åãã¯æ²»çããŠå¹Ÿå緩解ããïŒæ£
è ãã¯æ²»çããŠå®å šã«ç·©è§£ããïŒæ£è ã«ããã
ããã瀺ããŠããã第ïŒïŒå³ã§ã¯ãç æ°ã®äº¢é²ïœ
ãå埩ïœãäž¡æ¹å ±ããã€ãæ£è ã«ãããŠè¡æž dTk
ã瞊ã«è¿œè·¡ãããïŒã¯äº¢é²æ§çŸæ£ã®ïŒæ£è ã瀺
ãã圌çã¯æ²»çæ³ãå€ããåŸã幟å緩解ãããã®
åŸåã³ç æ°ã¯äº¢é²ãããïŒã¯æ²»çããŠç·©è§£ãã
ïŒæ£è ã®ãã®ã§ããïŒA.H.ïŒE.L.ã¯å¹Ÿå緩解ã
G.E.ã¯å®å šã«ç·©è§£ïŒã圌çå šå¡ã¯ãã®åŸåçºããã
A.H.ã¯ããäžåºŠãã®æ²»çã«çæéåå¿ããã以
äžã®çµæã¯ãæ²»çå¹æãç£èŠã§ããããšããããŠ
æ²»çäžã«ãæ²»çåŸã«ããdTkå€ã®å¢å ã«ãã€ãŠã
åçºã®æ©æçºèŠãã§ããããšãæããã«ç€ºããŠã
ãã æ¬çºæã«ããã¢ãã»ã€æ³ããã®ä»ã®äžèšãªã³ã
çå¢æ®æ§çŸæ£ãšé¢ä¿ã¥ããŠçšããå Žåãè¡æž dTk
ã¬ãã«ã®å€åãèŠåºããããäŸãã°æ ¢æ§CLLã¯
æ£åžžå€ãèŠåºãããããå掻æ§åCLLã§ã¯äœãã
ç çæ°å€ïŒïŒ10åäœïŒãšãªãã掻æ§CLLã¯é«ã
æ°å€ãäžãããNHLã§ç€ºãããããªdTkã¬ãã«
ã®å©çšã®ä»æ¹ã¯CLLã«ãããŠã¯ãŸãããã®äžã
çœè¡ç æ£è ããæ¡åããé«æ¶²ã®ç 究ã«ãããçœè¡
ç 现èãè³âèé«æ¶²äžã«ããæã«ã¯dTkãååšã
ãããšãå€ã€ãã åœç¶ãæªæ§çŸæ£æ£è ã«ãããŠãäžèšã®ãŠã€ãŒã«
ã¹æ§ææçã«ããâéæ§ã®è¡æž dTkã¬ãã«ã®äžæ
ããããåŸãããšã«ãæ°ãã€ããªããã°ãªããª
ããããããªãããããã®ãŠã€ãŒã«ã¹æ§çŸæ£ã«é¢
ããŠã¯ãåäŸã®é ã«å ç«ãç²åŸããŠããã®ãæ®é
ã§ãããäžæ¹ãæªæ§è «ççŸæ£ã¯ãæ®éãæ人ã«ã
ãããäžè¿°ã®ç®çã®ããã«è¡æž dTkã¬ãã«ãå©çš
ããããšãçã«å¶ãããäžã€ã®çç±ã¯ãæªç¢ºå®ã®
ç æ°ããã€ãæ£è ããæ¡åãã蚺æçç®çã®ãã
ã«é£ç¶çã«åŸãééžæçè¡æž è©Šæã®ç 究ã§ãdTk
掻æ§äžæã¯çšã«ããããããªãããšã§ããããã
ãã®æ£è ããã³ãã®ä»ã®æ£è ã«é¢ããå»åŠçèšé²
ã調ã¹ããšãèæ©èœæ€æ»ã®ç çæ°å€ãè¡æž çå¢å€
çãæ®éã¯è¡æž dTkã¬ãã«ã®äžæã䌎ããªãããš
ãå€æããã
ãæïŒããŒã«ã»ã·ã¹ãã ã«ããåé¡ïŒãé«ãdTk
ã¬ãã«ãšæªæ§åã®éã«ã¯ååãªçžé¢é¢ä¿ãèªãã
ãããïŒç¬¬ïŒå³åç §ãïŒæã«åããããæªæ§è «ç
ã®ç¬¬ãæã®NHLæ£è 101人ã«ãããè¡æž dTk
ã瀺ãïŒã æ¬çºæã«ããã¢ãã»ã€æ³ãäºåŸãç¥ãç®çã®ã
ãã«äœ¿çšãåŸãããšã蚌æããããããã¯ã枬å®
ããdTkå€ãïŒ10åäœã§ããããïŒ10åäœã§ãã
ãã«ãã€ãŠåé¡ããæ£è 矀ã®éã§ãçåæéã«é«
床ã«ææãªå·®ããããããããã§ããã第ïŒïŒïœ
å³ã¯ãããããã枬å®ããè¡æž dTkãïŒ10åäœ
ïŒâââââïŒïœïŒ50ïŒåã¯ïŒ10åäœïŒââââ
âïŒïœïŒ51ïŒã瀺ãããæã®NHLæ£è ã®ç
å確çã瀺ããã«ãã³å ã®æ°åã¯ã32ã±æåŸã®èŠ³
å¯æã«çãæ®ã€ãŠãã人æ°ã瀺ãã第ïŒïŒïœå³
ã¯ãâé«åºŠã«âæªæ§åããè «çããã€ããæ
ã®NHLæ£è ã«ã€ããŠã®çå確çã瀺ããããã
ãã枬å®ããdTkã¬ãã«ïŒïŒ10åäœïŒââââ
âïŒïœïŒ11ããã³ïŒ10åäœïŒâââââïŒïœïŒ
27ïŒãã«ãã³å ã®æ°åã¯32ã±æåŸã®èŠ³å¯æã«æ®ã€
ãŠãã人æ°ã§ããã æŽã«ãNHLæ£è ã®è¡æž dTkã¬ãã«ã®çµæç 究
ã¯ãç æ°ã®å€åã«çžé¢ããå€åãããããããå³
ã¡ç æ°ã®å埩ã§ãã®ã¬ãã«ã¯äœããªããç æ°ã®äº¢
é²ã§é«ããªããå®åžžç¶æ ã§ã¯å€åããªãã第ïŒïŒ
å³ã®ïŒ¡ã¯ã亢é²æã®ç æ°ã®ïŒæ£è ã®è¡æž dTkã¬ã
ã«æž¬å®å€ã®å€åãã¯æ²»çããŠå¹Ÿå緩解ããïŒæ£
è ãã¯æ²»çããŠå®å šã«ç·©è§£ããïŒæ£è ã«ããã
ããã瀺ããŠããã第ïŒïŒå³ã§ã¯ãç æ°ã®äº¢é²ïœ
ãå埩ïœãäž¡æ¹å ±ããã€ãæ£è ã«ãããŠè¡æž dTk
ã瞊ã«è¿œè·¡ãããïŒã¯äº¢é²æ§çŸæ£ã®ïŒæ£è ã瀺
ãã圌çã¯æ²»çæ³ãå€ããåŸã幟å緩解ãããã®
åŸåã³ç æ°ã¯äº¢é²ãããïŒã¯æ²»çããŠç·©è§£ãã
ïŒæ£è ã®ãã®ã§ããïŒA.H.ïŒE.L.ã¯å¹Ÿå緩解ã
G.E.ã¯å®å šã«ç·©è§£ïŒã圌çå šå¡ã¯ãã®åŸåçºããã
A.H.ã¯ããäžåºŠãã®æ²»çã«çæéåå¿ããã以
äžã®çµæã¯ãæ²»çå¹æãç£èŠã§ããããšããããŠ
æ²»çäžã«ãæ²»çåŸã«ããdTkå€ã®å¢å ã«ãã€ãŠã
åçºã®æ©æçºèŠãã§ããããšãæããã«ç€ºããŠã
ãã æ¬çºæã«ããã¢ãã»ã€æ³ããã®ä»ã®äžèšãªã³ã
çå¢æ®æ§çŸæ£ãšé¢ä¿ã¥ããŠçšããå Žåãè¡æž dTk
ã¬ãã«ã®å€åãèŠåºããããäŸãã°æ ¢æ§CLLã¯
æ£åžžå€ãèŠåºãããããå掻æ§åCLLã§ã¯äœãã
ç çæ°å€ïŒïŒ10åäœïŒãšãªãã掻æ§CLLã¯é«ã
æ°å€ãäžãããNHLã§ç€ºãããããªdTkã¬ãã«
ã®å©çšã®ä»æ¹ã¯CLLã«ãããŠã¯ãŸãããã®äžã
çœè¡ç æ£è ããæ¡åããé«æ¶²ã®ç 究ã«ãããçœè¡
ç 现èãè³âèé«æ¶²äžã«ããæã«ã¯dTkãååšã
ãããšãå€ã€ãã åœç¶ãæªæ§çŸæ£æ£è ã«ãããŠãäžèšã®ãŠã€ãŒã«
ã¹æ§ææçã«ããâéæ§ã®è¡æž dTkã¬ãã«ã®äžæ
ããããåŸãããšã«ãæ°ãã€ããªããã°ãªããª
ããããããªãããããã®ãŠã€ãŒã«ã¹æ§çŸæ£ã«é¢
ããŠã¯ãåäŸã®é ã«å ç«ãç²åŸããŠããã®ãæ®é
ã§ãããäžæ¹ãæªæ§è «ççŸæ£ã¯ãæ®éãæ人ã«ã
ãããäžè¿°ã®ç®çã®ããã«è¡æž dTkã¬ãã«ãå©çš
ããããšãçã«å¶ãããäžã€ã®çç±ã¯ãæªç¢ºå®ã®
ç æ°ããã€ãæ£è ããæ¡åãã蚺æçç®çã®ãã
ã«é£ç¶çã«åŸãééžæçè¡æž è©Šæã®ç 究ã§ãdTk
掻æ§äžæã¯çšã«ããããããªãããšã§ããããã
ãã®æ£è ããã³ãã®ä»ã®æ£è ã«é¢ããå»åŠçèšé²
ã調ã¹ããšãèæ©èœæ€æ»ã®ç çæ°å€ãè¡æž çå¢å€
çãæ®éã¯è¡æž dTkã¬ãã«ã®äžæã䌎ããªãããš
ãå€æããã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8203041A SE453514B (sv) | 1982-05-14 | 1982-05-14 | Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning |
| SE8203041-2 | 1982-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59500796A JPS59500796A (ja) | 1984-05-10 |
| JPH051000B2 true JPH051000B2 (ja) | 1993-01-07 |
Family
ID=20346817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58501735A Granted JPS59500796A (ja) | 1982-05-14 | 1983-05-10 | ïœïŒŽïœã¢ã€ãœã¶ã€ã 掻æ§ã®æž¬å®æ³ãšãã®å©çš |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4637977A (ja) |
| EP (1) | EP0094923B1 (ja) |
| JP (1) | JPS59500796A (ja) |
| AT (1) | ATE33504T1 (ja) |
| AU (1) | AU551176B2 (ja) |
| CA (1) | CA1199858A (ja) |
| DE (1) | DE3376272D1 (ja) |
| DK (1) | DK167692B1 (ja) |
| ES (1) | ES8402876A1 (ja) |
| FI (1) | FI77895C (ja) |
| SE (1) | SE453514B (ja) |
| WO (1) | WO1983004054A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816410A (en) * | 1986-10-29 | 1989-03-28 | Coulter Corporation | Control slide for immunoassay kit and method of making same |
| DE60217665T2 (de) * | 2002-07-27 | 2007-10-11 | Diasorin Ab | Verfahren zur Bestimmung der AktivitÀt von Thymidinkinase-1 und dessen Verwendung |
| KR101275585B1 (ko) | 2005-02-25 | 2013-06-19 | 뢎ë€ë¥Žë³Œ ìží°ëŽì ë ìë² | í°ë¯žë í€ëìì íì±ì ê²°ì íë ë°©ë² ë° í€íž ë° ê·žìì©ë |
| JP7560482B2 (ja) * | 2019-05-06 | 2024-10-02 | ã¢ãã»ã« ãšãŒã㌠| åŒåžåšææã®æ€åºããã³åé¡ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4302535A (en) * | 1979-09-27 | 1981-11-24 | Massachusetts Institute Of Technology | Assay for mutagenesis in heterozygous diploid human lymphoblasts |
| US4317877A (en) * | 1980-06-05 | 1982-03-02 | Sloan Kettering Institute | Process for detecting the presence of malignant and pre-malignant cells in humans |
| IE64317B1 (en) * | 1989-10-26 | 1995-07-26 | Walbro Corp | Fuel metering method and apparatus |
-
1982
- 1982-05-14 SE SE8203041A patent/SE453514B/sv not_active IP Right Cessation
-
1983
- 1983-05-10 AT AT83850122T patent/ATE33504T1/de not_active IP Right Cessation
- 1983-05-10 AU AU15540/83A patent/AU551176B2/en not_active Ceased
- 1983-05-10 DE DE8383850122T patent/DE3376272D1/de not_active Expired
- 1983-05-10 US US06/576,375 patent/US4637977A/en not_active Expired - Lifetime
- 1983-05-10 WO PCT/SE1983/000190 patent/WO1983004054A1/en not_active Ceased
- 1983-05-10 JP JP58501735A patent/JPS59500796A/ja active Granted
- 1983-05-10 EP EP83850122A patent/EP0094923B1/en not_active Expired
- 1983-05-13 CA CA000428172A patent/CA1199858A/en not_active Expired
- 1983-05-13 ES ES522376A patent/ES8402876A1/es not_active Expired
-
1984
- 1984-01-13 DK DK016384A patent/DK167692B1/da not_active IP Right Cessation
- 1984-01-13 FI FI840134A patent/FI77895C/fi not_active IP Right Cessation
Non-Patent Citations (3)
| Title |
|---|
| INFEC IMMUN=1980 * |
| INFEC IMMUN=1982 * |
| J.BIOL CHEM=1979 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0094923A2 (en) | 1983-11-23 |
| EP0094923B1 (en) | 1988-04-13 |
| DK16384D0 (da) | 1984-01-13 |
| SE8203041L (sv) | 1983-11-15 |
| DK16384A (da) | 1984-01-13 |
| FI840134A7 (fi) | 1984-01-13 |
| ATE33504T1 (de) | 1988-04-15 |
| AU1554083A (en) | 1983-12-02 |
| JPS59500796A (ja) | 1984-05-10 |
| AU551176B2 (en) | 1986-04-17 |
| US4637977A (en) | 1987-01-20 |
| FI77895C (fi) | 1989-05-10 |
| ES522376A0 (es) | 1984-03-01 |
| CA1199858A (en) | 1986-01-28 |
| FI840134A0 (fi) | 1984-01-13 |
| FI77895B (fi) | 1989-01-31 |
| ES8402876A1 (es) | 1984-03-01 |
| SE453514B (sv) | 1988-02-08 |
| WO1983004054A1 (en) | 1983-11-24 |
| EP0094923A3 (en) | 1985-07-24 |
| DE3376272D1 (en) | 1988-05-19 |
| DK167692B1 (da) | 1993-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chan et al. | Effectiveness of sodium fluoride as a preservative of glucose in blood. | |
| Maloney et al. | Distribution of suboptimally induced β-D-Galactosidase in Escherichia coli: the enzyme content of individual cells | |
| JP4901005B2 (ja) | 现èã¢ãã»ã€ãæ¹æ³åã³è©Šè¬ | |
| Stewart | Sensitive automated methods for phosphate and (Na++ K+)-ATPase | |
| Urdal et al. | Effects of Ca, Mg, and EDTA on creatine kinase activity in cerebrospinal fluid. | |
| Marche et al. | Metabolism of phosphoinositides in the rat erythrocyte membrane: A reappraisal of the effect of magnesium on the 32P incorporation into polyphosphoinositides | |
| US4080265A (en) | Method for the determination of creative phosphokinase enzyme | |
| CN109988816A (zh) | äžç§è ºè·è±æ°šé ¶æµå®è¯åç | |
| JPH051000B2 (ja) | ||
| JPH0687799B2 (ja) | é µçŽ é»å®³ã«ããããªãã€ãªã³ã®åæçšåæçŽ åïŒçµæç©ããã³æ¹æ³ | |
| Orfanos et al. | A rapid screening test for Duchenne muscular dystrophy using dried blood specimens | |
| Browning | Fluorometric enzyme assay for choline and acetylcholine | |
| Karmen et al. | Measurement of biliary alkaline phosphatase by mini-column chromatography and by electrophoresis and its application to the detection of liver metastases in patients with breast cancer. | |
| US3801466A (en) | Uric acid assay and reagents therefor | |
| US6861225B1 (en) | Method and reagent kit for determining activity of 5-nucleotidase | |
| Canbolat et al. | The comparison of adenosine deaminase activity values with polymerase chain reaction results in patients with tuberculosis | |
| Lundin et al. | Optimized bioluminescence assay of creatine kinase and creatine kinase B-subunit activity. | |
| Fingerman et al. | Defective Ca2+ metabolism in Duchenne muscular dystrophy: effects on cellular and viral growth. | |
| Raabo | Determination of serum lactic dehydrogenase by the tetrazolium salt method | |
| Rosano et al. | Evaluation of adenosine 5'-monophosphate and fluoride as adenylate kinase inhibitors in the creatine kinase assay. | |
| CN111057746B (zh) | äžç§èé žæ¿é ¶åå·¥é ¶æµå®è¯åç | |
| TWI275795B (en) | Novel assay method | |
| CA1070227A (en) | Measurement of alkaline phosphatase levels in body fluids | |
| BRPI0609044B8 (pt) | método e kit de ensaio para a determinação de atividade de timidina cinase em uma amostra biológica, uso de método e/ou de kit de ensaio, método para uso em diagnóstico, monitoramento e/ou prognóstico de doenças ou distúrbios de proliferação celular, e, método para uso em triagem de compostos | |
| Caines et al. | An improved fluorometric coupled enzymatic method for the determination of pyrophosphate in plasma and platelets |